0000000001180939

AUTHOR

Frauke Zipp

showing 167 related works from this author

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells

2014

Cladribine is a purine nucleoside analog developed to treat lymphoid malignancies. Reported therapeutic benefits for the autoimmune disease multiple sclerosis indicate additional immunomodulatory effects beyond the well-characterized cytotoxic activity causing lymphopenia. Here, we demonstrate that cladribine reduces the secretion of inflammatory cytokines and chemokines by murine and human dendritic cells, the most potent antigen-presenting cells. This compound also modulates the expression of the activation markers CD86 and MHC II. Furthermore, cladribine affects the T cell priming capacity of dendritic cells, resulting in reduced induction of interferon-γ- and tumor necrosis factor-α-pro…

Cell SurvivalT-LymphocytesT cellImmunologyBiologyMicePhagocytosismedicineAnimalsHumansImmunologic FactorsImmunology and AllergyCytotoxic T cellAntigen-presenting cellCladribineCells CulturedCell ProliferationPharmacologyCD86ChemotaxisCell DifferentiationDextransDendritic CellsDendritic cellmedicine.diseaseMice Inbred C57BLLeukemiamedicine.anatomical_structureImmunologyLeukocytes MononuclearCancer researchCladribineCytokinesTumor necrosis factor alphaFluorescein-5-isothiocyanatemedicine.drugInternational Immunopharmacology
researchProduct

Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation.

2021

Significance Multiple sclerosis (MS) is a neuroinflammatory, demyelinating disease that represents one of the most frequent causes of irreversible disability in young adults. Treatment options to halt disability are limited. We discovered that T helper (Th)17 cells in contact with oligodendrocytes produce higher levels of glutamate and induce significantly greater oligodendrocyte damage than their Th2 counterpart. Blockade of CD29, which is linked to glutamate release pathways and expressed in high levels on Th17 cells, preserved human oligodendrocyte processes from Th17-mediated injury. Our data thus provide evidence for the direct and deleterious attack of Th17 cells on the myelin compart…

Programmed cell deathEncephalomyelitis Autoimmune ExperimentalCentral nervous systemFreund's AdjuvantoligodendrocytesMice Transgenicglutamate03 medical and health sciencesMyelinMice0302 clinical medicineImmunology and Inflammationintravital microscopymedicineAnimalsNeuroinflammation030304 developmental biologyInflammationMice Knockout0303 health sciencesMultidisciplinaryChemistryMultiple sclerosisGlutamate receptorMembrane ProteinsCD29Biological SciencesCD29 blockademedicine.disease420Oligodendrocyte3. Good healthCell biologyDNA-Binding ProteinsMice Inbred C57BLOligodendrogliamedicine.anatomical_structurePertussis ToxinTh17 CellsMyelin-Oligodendrocyte Glycoprotein030217 neurology & neurosurgeryProceedings of the National Academy of Sciences of the United States of America
researchProduct

The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis

2017

Extracellular signal-regulated kinase (ERK) signaling plays a crucial role in regulating immune cell function and has been implicated in autoimmune disorders. To date, all commercially available inhibitors of ERK target upstream components, such as mitogen-activated protein (MAP) kinase/ERK kinase (MEKs), but not ERK itself. Here, we directly inhibit nuclear ERK translocation by a novel pharmacological approach (Glu-Pro-Glu (EPE) peptide), leading to an increase in cytosolic ERK phosphorylation during T helper (Th)17 cell differentiation. This was accompanied by diminished secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine influencing the encephalitogenicity …

0301 basic medicineMAPK/ERK pathwaymedicine.medical_treatmentCellular differentiationexperimental autoimmune encephalomyelitisLymphocyte Activationmedicine.disease_causemultiple sclerosisAutoimmunitylcsh:ChemistryMice0302 clinical medicineT-Lymphocyte SubsetsPhosphorylationExtracellular Signal-Regulated MAP Kinaseslcsh:QH301-705.5SpectroscopyKinaseExperimental autoimmune encephalomyelitisInterleukinGeneral MedicineComputer Science ApplicationsCell biologyProtein TransportCytokine030220 oncology & carcinogenesisFemaleERK pathwayCell signalingEncephalomyelitis Autoimmune ExperimentalMAP Kinase Signaling SystemT cellsBiologyModels BiologicalArticleCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalscell signalingPhysical and Theoretical ChemistryEPE peptideMolecular BiologyT cells; ERK pathway; EPE peptide; experimental autoimmune encephalomyelitis; multiple sclerosis; cell signalingOrganic ChemistryGranulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseDisease Models Animal030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Th17 CellsInternational Journal of Molecular Sciences
researchProduct

Role of Sortilin in Models of Autoimmune Neuroinflammation

2015

Abstract The proneurotrophin receptor sortilin is a protein with dual functions, being involved in intracellular protein transport, as well as cellular signal transduction. The relevance of the receptor for various neuronal disorders, such as dementia, seizures, and brain injury, is well established. In contrast, little is known about the role of sortilin in immune cells and inflammatory diseases. The aim of our study was to elucidate the distribution of sortilin in different immune cell types in mice and humans and to analyze its function in autoimmune CNS inflammation. Sortilin was expressed most profoundly in murine and human macrophages and dendritic cells and to a much lesser extent in…

Central Nervous SystemCell typeEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisT-LymphocytesEncephalomyelitisImmunologyAutoimmunityBiologyMiceImmune systemmedicineAnimalsHumansImmunology and AllergyReceptorNeuroinflammationMice KnockoutAutoimmune diseaseAntigen PresentationMacrophagesExperimental autoimmune encephalomyelitisDendritic Cellsmedicine.diseaseImmunity InnateMice Inbred C57BLAdaptor Proteins Vesicular TransportBrain InjuriesImmunologyNeurogenic InflammationSignal transductionSignal Transduction
researchProduct

Corrigendum to “Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans” [J. Neuroim…

2007

GeneticsLinkage disequilibriumJAG1Multiple sclerosisImmunologySusceptibility geneBiologymedicine.disease03 medical and health sciences0302 clinical medicineNeurologymedicineImmunology and AllergyNeurology (clinical)030215 immunologyJournal of Neuroimmunology
researchProduct

Power estimation for non-standardized multisite studies

2016

A concern for researchers planning multisite studies is that scanner and T1-weighted sequence-related biases on regional volumes could overshadow true effects, especially for studies with a heterogeneous set of scanners and sequences. Current approaches attempt to harmonize data by standardizing hardware, pulse sequences, and protocols, or by calibrating across sites using phantom-based corrections to ensure the same raw image intensities. We propose to avoid harmonization and phantom-based correction entirely. We hypothesized that the bias of estimated regional volumes is scaled between sites due to the contrast and gradient distortion differences between scanners and sequences. Given this…

Computer scienceCognitive Neurosciencecomputer.software_genreSensitivity and Specificity050105 experimental psychologyImaging phantomArticleSet (abstract data type)03 medical and health sciences0302 clinical medicineDistortionImage Interpretation Computer-AssistedCalibrationmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumans0501 psychology and cognitive sciencesSegmentationComputer Simulation10. No inequalityScalingModels Statisticalmedicine.diagnostic_test05 social sciencesContrast (statistics)BrainReproducibility of ResultsMagnetic resonance imagingEquipment DesignScale factorImage EnhancementMagnetic Resonance ImagingUnited StatesEquipment Failure AnalysisEuropeNeurologyOrdinary least squaresData miningFunction and Dysfunction of the Nervous SystemArtifactscomputer030217 neurology & neurosurgeryAlgorithms
researchProduct

Studying the blood-brain barrier will provide new insights into neurodegeneration - Commentary.

2018

0301 basic medicinebusiness.industryMultiple sclerosisNeurodegenerationNeurodegenerative DiseasesBlood–brain barriermedicine.disease03 medical and health sciences030104 developmental biologymedicine.anatomical_structureNeurologyBlood-Brain BarriermedicineAnimalsHumansNeurology (clinical)businessNeuroscienceMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation

2016

Genome-wide study in Germans identifies four novel multiple sclerosis risk genes and confirms already known gene loci.

0301 basic medicineMaleDLEU1MedizinGenome-wide association studyEpigenesis GeneticCohort StudiesResearch ArticlesTranscriptional Regulator ERGGeneticsAged 80 and overGlycine Hydroxymethyltransferaseeducation.field_of_studyMultidisciplinaryDNA methylationSciAdv r-articlesMiddle AgedSHMT13. Good healthddc:DNA-Binding ProteinsERGDNA methylationFemaleMAZFunction and Dysfunction of the Nervous SystemResearch ArticleAdultAdolescentPopulationQuantitative Trait Loci610 Medicine & healthDleu1 ; Dna Methylation ; Erg ; L3mbtl3 ; Maz ; Multiple Sclerosis ; Shmt1 ; Genome-wide Association StudyQuantitative trait locusBiologyMajor histocompatibility complexNeurological DisordersMultiple sclerosis03 medical and health sciencesYoung AdultTranscriptional Regulator ERGHumansGenetic Predisposition to DiseaseL3MBTL3EpigeneticsAlleleeducationAllelesAgedgenome-wide association study030104 developmental biologyGenetic LociCase-Control Studiesbiology.proteinTranscription Factors
researchProduct

In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.

2015

In multiple sclerosis (MS), a candidate downstream mechanism for neuronal injury is glutamate (Glu)-induced excitotoxicity, leading to toxic increases in intraneuronal Ca(2+) . Here, we used in vivo two-photon imaging in the brain of TN-XXL transgenic Ca(2+) reporter mice to test whether promising oral MS therapeutics, namely fingolimod, dimethyl fumarate, and their respective metabolites fingolimod-phosphate and monomethyl fumarate, can protect neurons against acute glutamatergic excitotoxic damage. We also assessed whether these drugs can protect against excitotoxicity in vitro using primary cortical neurons, and whether they can directly inhibit Glu release from pathogenic T-helper 17 ly…

0301 basic medicineKainic acidMultiple SclerosisExcitotoxicityGlutamic AcidPharmacologyBiologymedicine.disease_causeBiochemistryNeuroprotectionImmunomodulation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsCells CulturedNeuronsKainic AcidDimethyl fumarateCell DeathGlutamate receptorNeurotoxicityBrainmedicine.diseaseUp-Regulation030104 developmental biologyNeuroprotective AgentschemistryNMDA receptor030217 neurology & neurosurgerySignal TransductionJournal of neurochemistry
researchProduct

Bilateral vertebral artery dissection, agenesis of both ICAs, and connective tissue aberrations

2013

A 35-year-old woman presented with acute signs of stroke (appendix e-1 on the Neurology® Web site at [www.neurology.org][1]). After initial CT with angiography, MRI with time-of-flight angiography confirmed agenesis of both internal carotid arteries (ICAs; figure 1A). It revealed bilateral vertebral artery (VA) dissections and ischemias in both middle artery territories (figure 1, A–E). Skin biopsy microscopy (figure 2) was consistent with ultrastructural connective tissue disease (uCTD), for which no further evidence was found apart from mild hypermobility of the finger joints. The underlying uCTD with structural instability of the arterial walls and the increased blood flow in the vertebr…

Adultmedicine.medical_specialtyVertebral arteryConnective tissueMicroscopy Electron Transmissionmedicine.arteryHumansMedicineStrokeVertebral Artery Dissectionmedicine.diagnostic_testbusiness.industryAnatomymedicine.diseaseConnective tissue diseaseDissectionCarotid Arteriesmedicine.anatomical_structureConnective TissueAgenesisAngiographyFemaleNeurology (clinical)RadiologybusinessArteryNeurology
researchProduct

Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions

2021

Simple Summary Glioblastoma multiforme is a futile disease usually leading to the patient’s death within one year post-diagnosis; therefore, novel treatment options are desperately needed. In this regard, activation of the inert immune system has moved into focus in recent years. Malignant brain tumors, as well as autoimmune diseases, elicit aberrant immune responses. In this way, glioma escapes the host’s immune system and, thus, activation of the immune response in order to reduce tumor tolerance can serve as an alternative treatment option. Immune checkpoint modulators in combination with traditional therapies have gained attention in both glioma and autoimmune diseases. In this review, …

0301 basic medicineCancer Researchautoimmune disease ; immune checkpoints ; immunotherapy ; clinical trials ; Gliom ; gliomamedicine.medical_treatmentautoimmune diseaseContext (language use)Review03 medical and health sciences0302 clinical medicineImmune systemgliomaGliomamedicineRC254-282Autoimmune diseaseclinical trialsTumor microenvironmentbusiness.industryMultiple sclerosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunosuppressionImmunotherapybiochemical phenomena metabolism and nutritionimmune checkpointsmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchimmunotherapybusinessCancers
researchProduct

Neuropsychological Symptoms After Anterior Cerebral Artery Ischemic Stroke.

2020

medicine.medical_specialtyAnterior Cerebral Arterybusiness.industrymedia_common.quotation_subjectNeuropsychologyGeneral Medicinemedicine.diseaseNeglectBrain IschemiaCerebral AngiographyStrokeNeurologymedicine.arteryInternal medicineIschemic strokeAnterior cerebral arterymedicineCardiologyHumansNeurology (clinical)businessStrokemedia_commonIschemic StrokeThe Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
researchProduct

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

2013

Multiple sclerosis (MS) is a genetically complex disease that shares a substantial proportion of risk loci with other autoimmune diseases.1 Along these lines, ANKRD55 , originally implicated in rheumatoid arthritis, was recently reported as a potential novel MS risk gene (rs6859219, p=1.9×10−7).2 Here, we comprehensively validated this effect in independent datasets comprising 8846 newly genotyped subjects from Germany and France as well as 5003 subjects from two genome-wide association studies (GWAS). Upon meta-analysis of all available data (19 686 subjects), ANKRD55 rs6859219 now shows compelling evidence for association with MS at genome-wide significance (OR=1.19, p=3.1×10−11). Our stu…

RFXANKAdultMalemedicine.medical_specialtyMultiple SclerosisLocus (genetics)Genome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideWhite PeopleMolecular geneticsDatabases GeneticGeneticsmedicineHumansGenetic Predisposition to DiseaseGenetics (clinical)Genetic associationGeneticsMultiple sclerosisMiddle Agedmedicine.diseaseAnkyrin RepeatCase-Control StudiesAnkyrin repeatFemaleCarrier ProteinsGenome-Wide Association StudyJournal of medical genetics
researchProduct

New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis

2015

Multiple sclerosis is a chronic autoimmune demyelinating disease of the central nervous system, which is thought to be triggered by environmental factors in genetically susceptible individuals leading to activation of autoreactive T lymphocytes. Large multi-centre genome-wide association studies have identified multiple genetic risk loci in multiple sclerosis. In this study, we investigated T cell transcriptomic changes in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. We correlated these findings with the multiple sclerosis risk genes postulated by the most recent Immunochip analysis and found that multiple sclerosis susceptibility genes were significant…

CD4-Positive T-LymphocytesMice KnockoutEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisEffectorMultiple sclerosisT cellExperimental autoimmune encephalomyelitisGenome-wide association studyMERTKBiologymedicine.diseaseMice Inbred C57BLMicemedicine.anatomical_structureImmunologymedicineDemyelinating diseaseAnimalsHumansGene Regulatory NetworksNeurology (clinical)NeuroinflammationBrain
researchProduct

Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation.

2018

Ongoing axonal degeneration is thought to underlie disability in chronic neuroinflammation, such as multiple sclerosis (MS), especially during its progressive phase. Upon inflammatory attack, axons undergo pathological swelling, which can be reversible. Because we had evidence for beneficial effects of T helper 2 lymphocytes in experimental neurotrauma and discovered interleukin-4 receptor (IL-4R) expressed on axons in MS lesions, we aimed at unraveling the effects of IL-4 on neuroinflammatory axon injury. We demonstrate that intrathecal IL-4 treatment during the chronic phase of several experimental autoimmune encephalomyelitis models reversed disease progression without affecting inflamma…

0301 basic medicineMaleEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisEncephalomyelitisInflammation03 medical and health sciencesMice0302 clinical medicinemedicineAnimalsHumansAxonReceptorNeuroinflammationAdministration IntranasalInflammationNeuronsbusiness.industryMultiple sclerosisExperimental autoimmune encephalomyelitisTranslation (biology)General Medicinemedicine.diseaseAxonsReceptors Interleukin-4030104 developmental biologymedicine.anatomical_structurenervous systemInterleukin-4medicine.symptombusinessNeuroscience030217 neurology & neurosurgeryLocomotionScience translational medicine
researchProduct

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

2015

Objective: We aimed to clarify whether fingolimod has direct effects on antigen-presenting cells in multiple sclerosis patients. Methods: Frequency and phenotype of directly ex vivo dendritic cells and monocytes were analyzed in 43 individuals, including fingolimod-treated and untreated multiple sclerosis patients as well as healthy subjects. These cells were further stimulated with lipopolysaccharide to determine functional effects of fingolimod treatment. Results: Absolute numbers of CD1c+ dendritic cells and monocytes were not significantly reduced in fingolimod-treated patients indicating that fingolimod did not block the migration of antigen-presenting cells to peripheral blood. CD86 w…

AdultMaleMultiple Sclerosismedicine.medical_treatmentMonocytesYoung AdultMedicineHumansAntigen-presenting cellCD86business.industryFingolimod HydrochlorideMonocyteDendritic cellImmunotherapyDendritic CellsMiddle AgedFingolimodCytokinemedicine.anatomical_structureNeurologyImmunologyCytokinesFemaleNeurology (clinical)businessEx vivoImmunosuppressive Agentsmedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

2013

Laquinimod is an orally administered compound that is under investigation in relapsing-remitting multiple sclerosis. To understand the mechanism by which laquinimod exerts its clinical effects, we have performed human and murine studies assessing its immunomodulatory properties. In experimental autoimmune encephalomyelitis, the therapeutic administration of laquinimod beginning during the recovery of SJL mice, prevented further relapses as expected and strongly reduced infiltration of CD4+ and CD8+ T cells in the central nervous system. We hypothesized that this beneficial effect was mediated by dendritic cells, since we and others found a modulation of different dendritic cell subsets unde…

CD4-Positive T-LymphocytesChemokineEncephalomyelitis Autoimmune ExperimentalT cellQuinoloneschemistry.chemical_compoundMiceMultiple Sclerosis Relapsing-RemittingmedicineAnimalsHumansbiologyMonocyteExperimental autoimmune encephalomyelitisNF-kappa BDendritic cellDendritic Cellsmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structurechemistryImmunologybiology.proteinCytokine secretionFemaleNeurology (clinical)LaquinimodCD8Brain : a journal of neurology
researchProduct

Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity.

2018

T helper (Th)17 cells represent a unique subset of CD4(+) T cells and are vital for clearance of extracellular pathogens including bacteria and fungi. However, Th17 cells are also involved in orchestrating autoimmunity. By employing quantitative surface proteomics, we found that the evolutionarily conserved prohibitins (PHB1/2) are highly expressed on the surface of both murine and human Th17 cells. Increased expression of PHBs at the cell surface contributed to enhanced CRAF/MAPK activation in Th17 cells. Targeting surface‐expressed PHBs on Th17 cells with ligands such as Vi polysaccharide (Typhim vaccine) inhibited CRAF‐MAPK pathway, reduced interleukin (IL)‐17 expression and ameliorated …

0301 basic medicineMAPK/ERK pathwayMultiple SclerosisT cellCellPopulationAutoimmunityBiologymedicine.disease_causeT-Lymphocytes RegulatoryGeneral Biochemistry Genetics and Molecular BiologyAutoimmunity03 medical and health sciencesMiceProhibitinsRickettsial VaccinesmedicineAnimalsHumanseducationExtracellular Signal-Regulated MAP KinasesMolecular Biologyeducation.field_of_studyGeneral Immunology and MicrobiologyGeneral NeuroscienceInterleukinFOXP3Forkhead Transcription FactorsArticlesCell biologyRepressor Proteins030104 developmental biologymedicine.anatomical_structureTh17 CellsSignal transductionHeLa CellsSignal TransductionThe EMBO journal
researchProduct

Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation.

2017

GPCR expression was intensively studied in bulk cDNA of leukocyte populations, but limited data are available with respect to expression in individual cells. Here, we show a microfluidic-based single-cell GPCR expression analysis in primary T cells, myeloid cells, and endothelial cells under naive conditions and during experimental autoimmune encephalomyelitis, the mouse model of multiple sclerosis. We found that neuroinflammation induces characteristic changes in GPCR heterogeneity and patterning, and we identify various functionally relevant subgroups with specific GPCR profiles among spinal cord-infiltrating CD4 T cells, macrophages, microglia, or endothelial cells. Using GPCRs CXCR4, S1…

0301 basic medicineChemokinebiologyMicrogliaExperimental autoimmune encephalomyelitisCellInflammationGeneral Medicinemedicine.diseaseCell biology03 medical and health sciences030104 developmental biologymedicine.anatomical_structureImmune systemmedicinebiology.proteinmedicine.symptomNeuroinflammationG protein-coupled receptorResearch ArticleJCI insight
researchProduct

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study

2021

Background: Easily accessible biomarkers enabling the identification of those patients with multiple sclerosis (MS) who will accumulate irreversible disability in the long term are essential to guide early therapeutic decisions. We here examine the utility of serum neurofilament light chain (sNfL) for forecasting relapse-free disability progression and conversion to secondary progressive MS (SPMS) in the prospective Neurofilament and longterm outcome in MS (NaloMS) cohort. Methods: The predictive ability of sNfL at Baseline and sNfL follow-up (FU)/ Baseline (BL) ratio with regard to disability progression was assessed within a development cohort (NaloMS, n=196 patients with relapsing-remitt…

AdultMaleOncologymedicine.medical_specialtyMedicine (General)Logistic regressionGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosisYoung AdultMultiple Sclerosis Relapsing-RemittingR5-920Neurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansLongitudinal StudiesProspective StudiesRisk factorNeurofilament light chainSPMS transitionDisease progressionClinically isolated syndromebusiness.industryRGeneral MedicineOdds ratioMultiple Sclerosis Chronic ProgressiveConfidence intervalCohortMedicineFemalebusinessBiomarkersResearch PaperCohort studyEBioMedicine
researchProduct

Neurodegeneration in multiple sclerosis: novel treatment strategies.

2012

In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.

Multiple SclerosisInflammationNeuroprotectionmedicineAnimalsHumansPharmacology (medical)In patientMolecular Targeted TherapyNeuroinflammationNeuronsEvidence-Based Medicinebusiness.industryGeneral NeuroscienceMultiple sclerosisNeurodegenerationAnti-Inflammatory Agents Non-SteroidalNeurodegenerative Diseasesmedicine.diseasePathology of multiple sclerosisNeuroprotective AgentsTreatment strategyEducation Medical ContinuingNeurology (clinical)medicine.symptombusinessNeuroscienceExpert review of neurotherapeutics
researchProduct

Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis

2018

Background/aims Multiple sclerosis (MS) is a prototypical autoimmune central nervous system (CNS) disease. Particularly progressive forms of MS (PMS) show significant neuroaxonal damage as consequence of demyelination and neuronal hyperexcitation. Immuno-modulatory treatment strategies are beneficial in relapsing MS (RMS), but mostly fail in PMS. Pregabalin (Lyrica®) is prescribed to MS patients to treat neuropathic pain. Mechanistically, it targets voltage-dependent Ca2+ channels and reduces harmful neuronal hyperexcitation in mouse epilepsy models. Studies suggest that GABA analogues like pregabalin exert neuroprotective effects in animal models of ischemia and trauma. Methods We tested t…

0301 basic medicineCentral nervous systemPregabalinPregabalinPharmacologyNeuroprotectionlcsh:RC346-429Multiple sclerosis03 medical and health sciencesCellular and Molecular NeuroscienceDevelopmental Neurosciencemedicinelcsh:Neurology. Diseases of the nervous systemExperimental autoimmune encephalomyelitisMicrogliaVoltage-dependent calcium channelbusiness.industryMultiple sclerosislcsh:QP351-495Experimental autoimmune encephalomyelitismedicine.diseaseNeuroprotectionlcsh:Neurophysiology and neuropsychology030104 developmental biologymedicine.anatomical_structureNeurologyNeuropathic painbusinessmedicine.drugNeurosignals
researchProduct

MRI pattern recognition in multiple sclerosis normal-appearing brain areas

2011

ObjectiveHere, we use pattern-classification to investigate diagnostic information for multiple sclerosis (MS; relapsing-remitting type) in lesioned areas, areas of normal-appearing grey matter (NAGM), and normal-appearing white matter (NAWM) as measured by standard MR techniques.MethodsA lesion mapping was carried out by an experienced neurologist for Turbo Inversion Recovery Magnitude (TIRM) images of individual subjects. Combining this mapping with templates from a neuroanatomic atlas, the TIRM images were segmented into three areas of homogenous tissue types (Lesions, NAGM, and NAWM) after spatial standardization. For each area, a linear Support Vector Machine algorithm was used in mult…

AdultMalePathologymedicine.medical_specialtyMultiple SclerosisScienceNeuroimagingBiostatisticsGrey matterBiologycomputer.software_genreBrain mappingPattern Recognition Automated030218 nuclear medicine & medical imagingWhite matter03 medical and health sciences0302 clinical medicineText miningNeuroimagingVoxelImage Interpretation Computer-AssistedmedicineHumansMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisStatisticsQRBrainMagnetic resonance imagingmedicine.diseaseDemyelinating DisordersMagnetic Resonance Imagingmedicine.anatomical_structureNeurologyCase-Control StudiesMedicineFemalebusinesscomputerCartographyMathematics030217 neurology & neurosurgeryResearch Article
researchProduct

Testing different ICA algorithms and connectivity analyses on MS patients.

2015

Multiple sclerosis (MS) is a progressive neurological disorder that affects the central nervous system. Functional magnetic resonance imaging (fMRI) has been employed to track the course and disease progression in patients with MS. The two main aims of this study were to apply in a data-driven approach the independent component analysis (ICA) in the spatial domain to depict the active sources and to look at the effective connectivity between the identified spatial sources. Several ICA algorithms have been proposed for fMRI data analysis. In this study, we aimed to test two well characterized algorithms, namely, the fast ICA and the complex infomax algorithms, followed by two effective conne…

Brain MappingMultiple Sclerosismedicine.diagnostic_testComputer scienceMultiple sclerosisCentral nervous systemBrainMagnetic resonance imagingCoherence (statistics)Neurological disordermedicine.diseaseIndependent component analysisBrain mappingMagnetic Resonance Imagingmedicine.anatomical_structureRobustness (computer science)medicineHumansInfomaxFunctional magnetic resonance imagingAlgorithmDefault mode networkAlgorithmsAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
researchProduct

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing…

2017

Background: Currently, no unequivocal predictors of disease evolution exist in patients with multiple sclerosis (MS). Cortical atrophy measurements are, however, closely associated with cumulative disability. Objective: Here, we aim to forecast longitudinal magnetic resonance imaging (MRI)-driven cortical atrophy and clinical disability from cerebrospinal fluid (CSF) markers. Methods: We analyzed CSF fractions of albumin and immunoglobulins (Ig) A, G, and M and their CSF to serum quotients. Results: Widespread atrophy was highly associated with increased baseline CSF concentrations and quotients of albumin and IgA. Patients with increased CSFIgA and CSFIgM showed higher functional disabilit…

Immunoglobulin AAdultMalePathologymedicine.medical_specialty03 medical and health sciencesYoung Adult0302 clinical medicineCerebrospinal fluidMultiple Sclerosis Relapsing-RemittingAlbuminsmedicineHumansIn patient030212 general & internal medicineLongitudinal StudiesCortical atrophyCerebral Cortexbiologybusiness.industryMultiple sclerosisAlbuminmedicine.diseasePrognosisImmunoglobulin ADisease evolutionNeurologyRelapsing remittingbiology.proteinFemaleNeurology (clinical)Atrophybusiness030217 neurology & neurosurgeryBiomarkersMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Chemokine receptor CCR7 on CD4+ T cells plays a crucial role in the induction of experimental autoimmune encephalomyelitis

2014

CCR1Chemokine receptorNeurologyImmunologyExperimental autoimmune encephalomyelitisImmunologymedicineImmunology and AllergyC-C chemokine receptor type 7Neurology (clinical)Biologymedicine.diseaseCXCR3Journal of Neuroimmunology
researchProduct

Characterizing microstructural tissue properties in multiple sclerosis with diffusion MRI at 7 T and 3 T: The impact of the experimental design

2019

The recent introduction of advanced magnetic resonance (MR) imaging techniques to characterize focal and global degeneration in multiple sclerosis (MS), like the Composite Hindered and Restricted Model of Diffusion, or CHARMED, diffusional kurtosis imaging (DKI) and Neurite Orientation Dispersion and Density Imaging (NODDI) made available new tools to image axonal pathology non-invasively in vivo. These methods already showed greater sensitivity and specificity compared to conventional diffusion tensor-based metrics (e.g., fractional anisotropy), overcoming some of its limitations. While previous studies uncovered global and focal axonal degeneration in MS patients compared to healthy contr…

0301 basic medicineTime FactorsUltra-high field MRIAxonal pathologyCohort Studies0302 clinical medicineNuclear magnetic resonancemethods [Diffusion Magnetic Resonance Imaging]MicrostructureNODDImedicine.diagnostic_testGeneral NeuroscienceWATER DIFFUSIONmedicine.anatomical_structureResearch DesignKurtosisMulti-shell diffusion MRIAxonal degenerationWHITE-MATTERTENSORAdultMaterials sciencetherapy [Multiple Sclerosis]Sensitivity and SpecificityWhite matterMultiple sclerosis03 medical and health sciencesFractional anisotropyImage Interpretation Computer-Assistedmedicinediagnostic imaging [Nerve Degeneration]Journal ArticleHumansddc:610OPTIMIZATIONMultiple sclerosisinstrumentation [Diffusion Magnetic Resonance Imaging]diagnostic imaging [Multiple Sclerosis]Magnetic resonance imagingQUANTIFICATIONmedicine.diseaseMODELPATHOLOGYDiffusion Magnetic Resonance Imaging030104 developmental biologyRESOLUTIONDENSITYNerve Degeneration030217 neurology & neurosurgeryDiffusion MRI
researchProduct

Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniques

2019

Abstract Magnetic resonance imaging (MRI) is the most important tool for diagnosing multiple sclerosis (MS). However, MRI is still unable to precisely quantify the specific pathophysiological processes that underlie imaging findings in MS. Because autopsy and biopsy samples of MS patients are rare and biased towards a chronic burnt-out end or fulminant acute early stage, the only available methods to identify human disease pathology are to apply MRI techniques in combination with subsequent histopathological examination to small animal models of MS and to transfer these insights to MS patients. This review summarizes the existing combined imaging and histopathological studies performed in M…

0301 basic medicinePathologymedicine.medical_specialtyMultiple SclerosisNeuroimaging03 medical and health sciences0302 clinical medicineIn vivoBiopsymedicineAnimalsHumansStage (cooking)medicine.diagnostic_testbusiness.industryGeneral NeuroscienceMultiple sclerosisBrainMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingPathophysiology3. Good healthDisease Models AnimalEarly Diagnosis030104 developmental biologybusinessNeuroscience030217 neurology & neurosurgeryPreclinical imagingDiffusion MRIProgress in Neurobiology
researchProduct

Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

2012

Background Single nucleotide polymorphisms (SNPs) rs429358 (e4) and rs7412 (e2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently. Methods We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five ind…

GeneticsApolipoprotein E0303 health sciencesCandidate genebusiness.industrySingle-nucleotide polymorphismContext (language use)03 medical and health sciences0302 clinical medicineMeta-analysisImmunologyGenotypeGeneticsMedicinebusinessGenotyping030217 neurology & neurosurgeryGenetics (clinical)030304 developmental biologyGenetic associationJournal of Medical Genetics
researchProduct

Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)

2012

Objective: The current report provides detail on pooled analyses assessing the effect of laquinimod on relapse, disability, and brain atrophy measures from the recently completed phase III trials ALLEGRO and BRAVO. Background Laquinimod is an oral, CNS acting immunomodulator in development for the treatment of multiple sclerosis. Its impact on disability progression and brain atrophy, two indices of longterm outcome for patients with multiple sclerosis (MS) are being studied in its phase III trials. Design/Methods: MS patients (N=2437) were randomized to laquinimod (n=984) or placebo (n = 1006). In both trials, patients underwent neurological examinations including the Expanded Disability S…

medicine.medical_specialtyPhase iii trialsbusiness.industryRelapse ratePharmacologyClinical trialSafety profilechemistry.chemical_compoundchemistryFamily medicineMedicinemedia_common.cataloged_instanceDisability progressionNeurology (clinical)Clinical efficacyEuropean unionbusinessLaquinimodmedia_commonNeurology
researchProduct

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease …

2015

Background: Common symptoms of multiple sclerosis (MS) such as gait ataxia, poor coordination of the hands, and intention tremor are usually the result of dysfunctionality in the cerebellum. Magnetic resonance imaging (MRI) has frequently failed to detect cerebellar damage in the form of inflammatory lesions in patients presenting with symptoms of cerebellar dysfunction. Objective: To detect microstructural cerebellar tissue alterations in early MS patients with a “normal appearing” cerebellum using diffusion tensor imaging (DTI). Methods: A total of 68 patients with relapsing–remitting MS (RRMS) and without cerebellar lesions and 26 age-matched healthy controls were admitted to high-resolu…

AdultMaleCerebellumPathologymedicine.medical_specialtyTime FactorsSeverity of Illness Index030218 nuclear medicine & medical imagingYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineAtrophyCerebellar DiseasesFractional anisotropymedicineHumansmedicine.diagnostic_testMultiple sclerosisMagnetic resonance imagingMiddle Agedmedicine.diseaseWhite MatterDiffusion Tensor Imagingmedicine.anatomical_structurenervous systemNeurologyGait AtaxiaFemaleIntention tremorNeurology (clinical)Atrophymedicine.symptomPsychology030217 neurology & neurosurgeryDiffusion MRIMultiple Sclerosis Journal
researchProduct

A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis.

2015

Aim The evaluation of inner retinal layer thickness can serve as a direct biomarker for monitoring the course of inflammatory diseases of the central nervous system such as multiple sclerosis (MS). Using optical coherence tomography (OCT), thinning of the retinal nerve fibre layer and changes in deeper retinal layers have been observed in patients with MS. Here, we first compare a novel method for automated segmentation of OCT images with manual segmentation using two cohorts of patients with MS. Using this method, we also aimed to reproduce previous findings showing retinal degeneration following optic neuritis (ON) in MS. Methods Based on a 5×5 expansion of the Prewitt operator to efficie…

Retinal degenerationAdultMalePathologymedicine.medical_specialtyMultiple SclerosisOptic Neuritisgenetic structuresDiagnostic Techniques Ophthalmological03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundYoung Adult0302 clinical medicineNerve FibersOptical coherence tomographyOphthalmologyMedicineHumansSegmentationOptic neuritisGanglion cell layerRetinamedicine.diagnostic_testbusiness.industryRetinal DegenerationReproducibility of ResultsRetinalMiddle Agedmedicine.diseaseeye diseasesSensory SystemsOphthalmologymedicine.anatomical_structurechemistry030221 ophthalmology & optometryOptic nerveFemalesense organsbusiness030217 neurology & neurosurgeryAlgorithmsBiomarkersTomography Optical CoherenceRetinal NeuronsThe British journal of ophthalmology
researchProduct

A Novel Cervical Spinal Cord Window Preparation Allows for Two-Photon Imaging of T-Cell Interactions with the Cervical Spinal Cord Microvasculature d…

2017

T-cell migration across the blood-brain barrier (BBB) is a crucial step in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple scle rosis (MS). Two-photon intravital microscopy (2P-IVM) has been established as a powerful tool to study cell-cell interactions in inflammatory EAE lesions in living animals. In EAE, central nervous system inflammation is strongly pronounced in the spinal cord, an organ in which 2P-IVM imaging is technically very challenging and has been limited to the lumbar spinal cord. Here, we describe a novel spinal cord window preparation allowing to use 2P-IVM to image immune cell interactions with the cervical spinal cord micro…

0301 basic medicinePathologymedicine.medical_specialtyImmunologyCentral nervous systemexperimental autoimmune encephalomyelitis610 Medicine & healthblood–brain barrierBlood–brain barrier03 medical and health sciences0302 clinical medicineMethodsmedicineImmunology and Allergy610 Medicine & healthtwo-photon intravital microscopybusiness.industrycervical spinal cord windowMultiple sclerosisExperimental autoimmune encephalomyelitis500 Sciencemedicine.diseaseSpinal cordExtravasationLumbar Spinal Cord030104 developmental biologymedicine.anatomical_structurebusinessT-cell migration030217 neurology & neurosurgeryIntravital microscopyFrontiers in Immunology
researchProduct

Potential drug targets for oral medications

2012

Drugbusiness.industrymedia_common.quotation_subjectMedicinePharmacologybusinessmedia_commonEmerging Oral Medications for Multiple Sclerosis
researchProduct

Molecular mechanisms linking neuroinflammation and neurodegeneration in MS.

2013

Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disorder of the central nervous system (CNS) and one of the leading causes of neurological deficits and disability in young adults in western countries. Current medical treatment mainly influences disease progression via immunomodulatory or immunosuppressive actions. Indeed, MS research has been foremost focused on inflammation in the CNS, but more recent evidence suggests that chronic disability in MS is caused by neurodegeneration. Imaging studies show an early involvement of neurodegeneration as brain atrophy and gray matter lesions can be observed at disease onset. Thus, neuroprotective treatment strategies and the eluc…

Central Nervous SystemMultiple SclerosisCentral nervous systemBiologyNeuroprotectionPathogenesisAtrophyDevelopmental NeurosciencemedicineAnimalsHumansImmunologic FactorsNeuroinflammationInflammationMultiple sclerosisExperimental autoimmune encephalomyelitisNeurodegenerationmedicine.diseaseDisease Models Animalmedicine.anatomical_structureNeurologyImmunologyNerve DegenerationDisease ProgressionCytokinesNeuroscienceExperimental neurology
researchProduct

Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis

2016

Background: The pathology of multiple sclerosis (MS) consists of demyelination and neuronal injury, which occur early in the disease; yet, remission phases indicate repair. Whether and how the central nervous system (CNS) maintains homeostasis to counteract clinical impairment is not known. Objective: We analyse the structural connectivity of white matter (WM) and grey matter (GM) networks to understand the absence of clinical decline as the disease progresses. Methods: A total of 138 relapsing–remitting MS patients (classified into six groups by disease duration) and 32 healthy controls were investigated using 3-Tesla magnetic resonance imaging (MRI). Networks were analysed using graph the…

AdultMale0301 basic medicineMultiple SclerosisModularity (biology)DiseaseGrey matterBiologyNerve Fibers MyelinatedYoung Adult03 medical and health sciences0302 clinical medicineImage Processing Computer-AssistedmedicineHumansGray MatterMultiple sclerosisMiddle Agedmedicine.diseaseNetwork dynamicsWhite MatterPathology of multiple sclerosisWhite (mutation)Diffusion Tensor Imaging030104 developmental biologymedicine.anatomical_structureNeurologyFemaleNeurology (clinical)Nerve NetAdaptationNeuroscience030217 neurology & neurosurgeryDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Testing direct neuroprotective effects of current MS therapeutic compounds with intravital two photon laser scanning microscopy

2014

Laser Scanning MicroscopyMaterials scienceNeurologyTwo-photon excitation microscopybusiness.industryImmunologyImmunology and AllergyOptoelectronicsNeurology (clinical)Current (fluid)businessNeuroprotectionJournal of Neuroimmunology
researchProduct

Protein kinase CK2 governs the molecular decision between encephalitogenic T H 17 cell and T reg cell development

2016

T helper 17 (TH17) cells represent a discrete TH cell subset instrumental in the immune response to extracellular bacteria and fungi. However, TH17 cells are considered to be detrimentally involved in autoimmune diseases like multiple sclerosis (MS). In contrast to TH17 cells, regulatory T (Treg) cells were shown to be pivotal in the maintenance of peripheral tolerance. Thus, the balance between Treg cells and TH17 cells determines the severity of a TH17 cell-driven disease and therefore is a promising target for treating autoimmune diseases. However, the molecular mechanisms controlling this balance are still unclear. Here, we report that pharmacological inhibition as well as genetic ablat…

STAT3 Transcription Factor0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisCellMice Transgenicchemical and pharmacologic phenomenaBiologySeverity of Illness IndexT-Lymphocytes RegulatoryMice03 medical and health sciences0302 clinical medicineImmune systemmedicineAnimalsHumansIL-2 receptorPhosphorylationCasein Kinase IISTAT3MultidisciplinaryCell growthInterleukin-17Experimental autoimmune encephalomyelitisGranulocyte-Macrophage Colony-Stimulating FactorFOXP3Peripheral toleranceForkhead Transcription Factorshemic and immune systemsReceptors Interleukinmedicine.diseasePeptide FragmentsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureGene Expression RegulationImmunologybiology.proteinCancer researchTh17 CellsMyelin-Oligodendrocyte GlycoproteinSignal Transduction030215 immunologyProceedings of the National Academy of Sciences
researchProduct

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

2017

Abstract The therapeutic mode of action of dimethyl fumarate (DMF), approved for treating patients with relapsing-remitting multiple sclerosis, is not fully understood. Recently, we and others demonstrated that Ab-independent functions of distinct B cell subsets are important in mediating multiple sclerosis (MS) relapsing disease activity. Our objective was to test whether and how DMF influences both the phenotype and functional responses of disease-implicated B cell subsets in patients with MS. High-quality PBMC were obtained from relapsing-remitting MS patients prior to and serially after initiation of DMF treatment. Multiparametric flow cytometry was used to monitor the phenotype and fun…

AdultMale0301 basic medicineDimethyl FumarateImmunologyNaive B cellB-Lymphocyte SubsetsEnzyme-Linked Immunosorbent AssayBiologyPeripheral blood mononuclear cellProinflammatory cytokineFlow cytometryYoung Adult03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineIn vivomedicineHumansImmunology and AllergyB cellmedicine.diagnostic_testDimethyl fumarateMultiple sclerosisMiddle AgedFlow Cytometrymedicine.disease030104 developmental biologymedicine.anatomical_structurechemistryImmunologyCancer researchFemaleImmunosuppressive Agents030217 neurology & neurosurgeryThe Journal of Immunology
researchProduct

An improved anatomical MRI technique with suppression of fixative fluid artifacts for the investigation of human postmortem brain phantoms

2016

PURPOSE Phantoms are often used to assess MR system stability in multicenter studies. Postmortem brain phantoms best replicate human brain anatomy, allowing for a combined assessment of the MR system and software chain for data analysis. However, a wash-out of fixative fluid affecting T1 values and thus T1-weighted sequences such as magnetization-prepared 180 degrees radiofrequency pulses and rapid gradient-echo (MP-RAGE) has been reported for brain phantoms, hampering their immediate use. The purpose of this study was the creation of anatomical data that provide the characteristics of conventional data while avoiding this artifact. THEORY AND METHODS Two brain phantoms were scanned at seve…

Pathologymedicine.medical_specialtymedicine.diagnostic_testPostmortem brainComputer scienceSystem stabilityMagnetic resonance imagingHuman brainequipment and suppliesSynthetic data030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structuremedicineRadiology Nuclear Medicine and imagingProton density030217 neurology & neurosurgeryFixativeBiomedical engineeringFixation (histology)Magnetic Resonance in Medicine
researchProduct

The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients

2015

Infratentorial lesions have been assigned an equivalent weighting to supratentorial plaques in the new McDonald criteria for diagnosing multiple sclerosis. Moreover, their presence has been shown to have prognostic value for disability. However, their spatial distribution and impact on network damage is not well understood. As a preliminary step in this study, we mapped the overall infratentorial lesion pattern in relapsing–remitting multiple sclerosis patients (N = 317) using MRI, finding the pons (lesion density, 14.25/cm3) and peduncles (13.38/cm3) to be predilection sites for infratentorial lesions. Based on these results, 118 fiber bundles from 15 healthy controls and a subgroup of 23 …

AdultPathologymedicine.medical_specialtyWallerian degenerationCognitive Neurosciencelcsh:Computer applications to medicine. Medical informaticsArticlelcsh:RC346-429LesionWhite matterMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNerve FibersLSAF left superior arcuate fasciculusFractional anisotropymedicineHumansRadiology Nuclear Medicine and imagingFA fractional anisotropyNAWM normal-appearing white matterLD lesion densitylcsh:Neurology. Diseases of the nervous systemEAE experimental autoimmune encephalomyelitisMD mean diffusivitybusiness.industryMultiple sclerosisWhite matterMcDonald criteriaMiddle Agedmedicine.diseaseRD radial diffusivitymedicine.anatomical_structureDiffusion tensor imagingNeurologylcsh:R858-859.7Neurology (clinical)Brainstemmedicine.symptomFunction and Dysfunction of the Nervous SystembusinessBrainstemAD axial diffusivityDiffusion MRIBrain StemICP inferior cerebellar peduncleFractional anisotropyNeuroImage: Clinical
researchProduct

Understanding the Role of T Cells in CNS Homeostasis.

2015

T cells within the central nervous system (CNS) have been generally considered pathogenic, especially in the context of neuroinflammatory disease. However, recent findings have revealed varied functions for T cells in the healthy CNS, as well as more complex roles for these cells in infection and injury than previously appreciated. Here we review evidence indicating important roles for different T cell subsets in the maintenance of CNS homeostasis. We examine the contribution of T cells in limiting inflammation and damage upon CNS injury, infection, and in neurodegeneration, and discuss the current understanding of the cellular and molecular mechanisms involved. Insight into these processes…

Central Nervous SystemT cellT-LymphocytesImmunologyCentral nervous systemContext (language use)InflammationDiseaseBiologyLymphocyte Depletion03 medical and health sciences0302 clinical medicineT-Lymphocyte SubsetsmedicineImmunology and AllergyAnimalsHomeostasisHumansNeurodegenerationmedicine.diseaseCns injurymedicine.anatomical_structureImmunologymedicine.symptomNeurogenic Inflammation030217 neurology & neurosurgeryHomeostasis030215 immunologyTrends in immunology
researchProduct

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

2011

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals, and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk. Modestly powered genome-wide association studies (GWAS) have ena…

Immunity Cellular/geneticsCellular immunityMultiple SclerosisGenome-wide association studyCLEC16ABiologyPolymorphism Single NucleotideCell Differentiation/immunologyEurope/ethnologyMajor Histocompatibility Complex/geneticsMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinemedicineGenetic predispositionHumansGenetic Predisposition to DiseaseHLA-A Antigens/geneticsAlleles030304 developmental biologyGenetic associationGenetics0303 health sciencesImmunity CellularMultidisciplinaryHLA-A AntigensGenome HumanMultiple sclerosisGenetic Predisposition to Disease/geneticsHLA-DR Antigens/geneticsLymphocyte differentiationCell DifferentiationHLA-DR AntigensT-Lymphocytes Helper-InducerRC346medicine.diseasePolymorphism Single Nucleotide/geneticsGenetic architecture3. Good healthEuropeSample SizeImmunologyGenome Human/geneticsMultiple Sclerosis/genetics030217 neurology & neurosurgeryT-Lymphocytes Helper-Inducer/cytologyGenome-Wide Association StudyHLA-DRB1 Chains
researchProduct

Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study

2020

Abstract Background We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients. Methods In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up. Findings Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (R…

0301 basic medicineAdultMalemedicine.medical_specialtyResearch paperClinical Decision-MakingIntermediate Filamentslcsh:Medicine610 Medicine & healthNewly diagnosedGeneral Biochemistry Genetics and Molecular BiologyMultiple sclerosis03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInternal medicineGermanymedicineHumansLongitudinal StudiesProspective Studiesddc:610610 Medicine & healthNeurofilament light chainlcsh:R5-920Clinically isolated syndromebusiness.industryMultiple sclerosislcsh:RMcDonald criteriaGeneral MedicineBiomarkermedicine.diseasesNfL030104 developmental biology030220 oncology & carcinogenesisCohortDisease ProgressionCommentaryBiomarker (medicine)Femalelcsh:Medicine (General)businessPredictionFunction and Dysfunction of the Nervous SystemBiomarkersCohort study
researchProduct

Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study.

2011

Background: Sleep disorders can cause tiredness. The relationship between sleep disorders and fatigue in patients with multiple sclerosis (MS) has not yet been investigated systematically. Objective: To investigate the relationship between fatigue and sleep disorders in patients with MS. Methods: Some 66 MS patients 20 to 66 years old were studied by overnight polysomnography. Using a cut-off point of 45 in the Modified Fatigue Impact Scale (MFIS), the entire cohort was stratified into a fatigued MS subgroup ( n = 26) and a non-fatigued MS subgroup ( n = 40). Results: Of the fatigued MS patients, 96% ( n = 25) were suffering from a relevant sleep disorder, along with 60% of the non-fatigue…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyPeriodic limb movement disorderMultiple SclerosisPolysomnographyNeurological disorderPolysomnographyRisk AssessmentCentral nervous system diseaseYoung AdultRisk FactorsInternal medicineGermanySurveys and QuestionnairesmedicineInsomniaOdds RatioHumansRestless legs syndromeFatigueAgedSleep disordermedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseCross-Sectional StudiesLogistic ModelsNeurologyCohortPhysical therapyFemaleNeurology (clinical)medicine.symptombusinessSleepMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.

2021

The past decades have yielded major therapeutic advances in many autoimmune conditions – such as multiple sclerosis (MS) – and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy much more challenging for the attending physician, especially when treating patients with more than one autoimmune condition. Importantly, some therapeutic strategies are either approved for several autoimmune disorders or may be repurposed for other conditions, therefore opening new curative possibilities in related fields. In this article, we especially focus on frequent and therapeutically rele…

rheumatoid arthritismedicine.medical_specialtymedicine.medical_treatmentPsychological interventionReviewmultiple sclerosisInflammatory bowel diseaseinflammatory bowel diseasePsoriasismedicineRC346-429Intensive care medicinePharmacologybusiness.industryMultiple sclerosisInflammatory Bowel DiseasesImmunotherapypsoriasismedicine.diseaseNeurologyRheumatoid arthritisNeurology. Diseases of the nervous systemNeurology (clinical)immunotherapyAutoimmune conditionbusinessTherapeutic advances in neurological disorders
researchProduct

Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis

2021

Background: Serum neurofilament light chain (sNfL) and distinct intra-retinal layers are both promising biomarkers of neuro-axonal injury in multiple sclerosis (MS). We aimed to unravel the association of both markers in early MS, having identified that neurofilament has a distinct immunohistochemical expression pattern among intra-retinal layers. Methods: Three-dimensional (3D) spectral domain macular optical coherence tomography scans and sNfL levels were investigated in 156 early MS patients (female/male: 109/47, mean age: 33.3 ± 9.5 years, mean disease duration: 2.0 ± 3.3 years). Out of the whole cohort, 110 patients had no history of optic neuritis (NHON) and 46 patients had a previous…

Advances in Neuroimaging0301 basic medicinePathologymedicine.medical_specialtyNeurofilamentNeurofilament lighttranslationneuroimmunologymultiple sclerosisserum neurofilament03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOptical coherence tomographyMedicineOptic neuritisRC346-429Original Researchoptic neuritisPharmacologyoptical coherence tomographymedicine.diagnostic_testbusiness.industryMultiple sclerosisRetinalmedicine.disease030104 developmental biologyNeuroimmunologyNeurologychemistryNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients

2014

Background and PurposezzThe aim of this study was to elucidate the role of therapy-related cardiotoxicity in multiple sclerosis (MS) patients treated with mitoxantrone and to identify potential predictors for individual risk assessment. MethodszzWithin a multicenter retrospective cohort design, cardiac side effects attributed to mitoxantrone were analyzed in 639 MS patients at 2 MS centers in Germany. Demographic, disease, treatment, and follow-up data were collected from hospital records. Patients regularly received cardiac monitoring during the treatment phase. ResultszzNone of the patients developed symptomatic congestive heart failure. However, the frequency of patients experiencing car…

Cardiac function curvemedicine.medical_specialtyCardiotoxicityMitoxantronedose dependencybusiness.industryCumulative doseMultiple sclerosiscardiotoxicityRetrospective cohort studymultiple sclerosismedicine.diseasemitoxantroneNeurologyInternal medicineCohortmedicineOriginal ArticleNeurology (clinical)Risk factorbusinessIntensive care medicineFunction and Dysfunction of the Nervous Systemmedicine.drug
researchProduct

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS

2018

ObjectiveTo describe a case of glial fibrillary acidic protein (GFAP)α immunoglobulin G (IgG)-associated encephalitis in a patient referred to us with MS on daclizumab treatment and to summarize characteristics of 5 additional recent German MS cases of serious encephalitis along with a previously published American case of CNS vasculitis associated with daclizumab.MethodsEvaluation of cause, clinical symptoms, and treatment response.ResultsThe 6 patients included 4 women and 2 men. The median age at onset was 38 years (range 32–51 years). Clinical presentation was marked by progressing neuropsychologic and/or neurologic deficits. Additional drug rash with eosinophilia was seen in 3 patients…

0301 basic medicine41132medicine.disease_causeArticleImmunoglobulin GAutoimmunity03 medical and health sciences0302 clinical medicineDaclizumabmedicineEosinophiliaPleocytosisbiologyGlial fibrillary acidic proteinbusiness.industrymedicine.disease030104 developmental biologyNeurologyImmunologybiology.proteinNeurology (clinical)medicine.symptomAntibodybusiness030217 neurology & neurosurgeryEncephalitismedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

Multiple sclerosis severity score: Using disability and disease duration to rate disease severity

2005

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. I…

AdultMalemedicine.medical_specialtyMultiple SclerosisDatabases FactualCross-sectional studyModels NeurologicalDiseaseSUSCEPTIBILITYSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsRecurrenceSeverity of illnessmedicineHumansLongitudinal StudiesAge of OnsetModels StatisticalExpanded Disability Status Scalebusiness.industryMultiple sclerosisOUTCOME MEASUREReproducibility of ResultsNATURAL-HISTORYMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesPredictive value of testsDisease ProgressionPhysical therapyFemaleFranceNeurology (clinical)Age of onsetbusinessCohort study
researchProduct

Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging

2019

Longitudinal analysis of white matter lesion changes on serial MRI has become an important parameter to study diseases with white-matter lesions. Here, we build on earlier work on cross-sectional lesion segmentation; we present a fully automatic pipeline for serial analysis of FLAIR-hyperintense white matter lesions. Our algorithm requires three-dimensional gradient echo T1- and FLAIR- weighted images at 3 Tesla as well as available cross-sectional lesion segmentations of both time points. Preprocessing steps include lesion filling and intrasubject registration. For segmentation of lesion changes, initial lesion maps of different time points are fused; herein changes in intensity are analyz…

AdultMaleMultiple SclerosisCognitive Neuroscience610Fluid-attenuated inversion recoverylcsh:Computer applications to medicine. Medical informaticscomputer.software_genrelcsh:RC346-429050105 experimental psychologyCohort StudiesWhite matterLesionYoung Adult03 medical and health sciences0302 clinical medicineSørensen–Dice coefficientVoxelmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingSegmentationLongitudinal Studieslcsh:Neurology. Diseases of the nervous systemmedicine.diagnostic_testbusiness.industry05 social sciencesRegular ArticleMagnetic resonance imagingLesion segmentation; Magnetic resonance imaging; Multiple sclerosis; White matter lesionsMiddle AgedMagnetic Resonance ImagingHyperintensityddc:Cross-Sectional Studiesmedicine.anatomical_structureNeurologylcsh:R858-859.7FemaleNeurology (clinical)medicine.symptombusinessNuclear medicinecomputer030217 neurology & neurosurgeryFollow-Up StudiesNeuroImage: Clinical
researchProduct

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array

2015

Genome-wide association studies (GWAS) successfully identified various chromosomal regions to be associated with multiple sclerosis (MS). The primary aim of this study was to replicate reported associations from GWAS using an exome array in a large German study. German MS cases (n = 4,476) and German controls (n = 5,714) were genotyped using the Illumina HumanExome v1-Chip. Genotype calling was performed with the Illumina Genome Studio(TM) Genotyping Module, followed by zCall. Single-nucleotide polymorphisms (SNPs) in seven regions outside the human leukocyte antigen (HLA) region showed genome-wide significant associations with MS (P values < 5 × 10(-8) ). These associations have been repor…

Geneticseducation.field_of_studyEpidemiologyPopulationGenome-wide association studySingle-nucleotide polymorphismHuman leukocyte antigenBiologySNPeducationExomeGenotypingGenetics (clinical)Genetic associationGenetic Epidemiology
researchProduct

Cross-recognition of a myelin peptide by CD8+ T cells in the CNS is not sufficient to promote neuronal damage.

2015

Multiple sclerosis (MS) is an inflammatory disease of the CNS thought to be driven by CNS-specific T lymphocytes. Although CD8+T cells are frequently found in multiple sclerosis lesions, their distinct role remains controversial because direct signs of cytotoxicity have not been confirmedin vivo. In the present work, we determined that murine ovalbumin-transgenic (OT-1) CD8+T cells recognize the myelin peptide myelin oligodendrocyte glycoprotein 40–54 (MOG40–54) bothin vitroandin vivo. The aim of this study was to investigate whether such cross-recognizing CD8+T cells are capable of inducing CNS damagein vivo. Using intravital two-photon microscopy in the mouse model of multiple sclerosis, …

CD4-Positive T-LymphocytesCentral Nervous SystemMaleEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisAutoimmunityMice TransgenicCD8-Positive T-Lymphocytesmedicine.disease_causeMyelin oligodendrocyte glycoproteinMyelinMiceIn vivomedicineCytotoxic T cellAnimalsCells CulturedCell ProliferationbiologyCell DeathGeneral NeuroscienceMultiple sclerosisArticlesmedicine.diseaseMolecular mimicrymedicine.anatomical_structureImmunologyNerve Degenerationbiology.proteinFemaleMyelin-Oligodendrocyte GlycoproteinCD8Intravital microscopyThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Ocrelizumab initiation in patients with MS

2020

ObjectiveTo provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab.MethodsWe retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients' characteristics including premedication, clinical disease course, and documented side effects were analyzed.ResultsWe could identify 210 patients (125 women, mean age ± SD, 42.1 ± 11.4 years) who had received ocrelizumab with a mean disease duration of 7.3 years and a median Expanded Disability Status Scale score of 3.75 (interquartile range 2.5–5.5; range 0–8). Twenty-six percent of these patients had a pr…

medicine.medical_specialtyNeurologyExpanded Disability Status Scalebusiness.industryFingolimod03 medical and health sciences0302 clinical medicineNatalizumabNeurologyInterquartile rangeInternal medicinemedicineOcrelizumabObservational studyPremedication030212 general & internal medicineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

β1-Integrin– and K(V)1.3 channel–dependent signaling stimulates glutamate release from Th17 cells

2020

Although the impact of Th17 cells on autoimmunity is undisputable, their pathogenic effector mechanism is still enigmatic. We discovered soluble N-ethylmaleimide–sensitive factor attachment receptor (SNARE) complex proteins in Th17 cells that enable a vesicular glutamate release pathway that induces local intracytoplasmic calcium release and subsequent damage in neurons. This pathway is glutamine dependent and triggered by binding of β1-integrin to vascular cell adhesion molecule 1 (VCAM-1) on neurons in the inflammatory context. Glutamate secretion could be blocked by inhibiting either glutaminase or K(V)1.3 channels, which are known to be linked to integrin expression and highly expressed…

0301 basic medicineMultiple SclerosisGlutamic AcidVascular Cell Adhesion Molecule-1Cell Communication03 medical and health sciencesMice0302 clinical medicineAnimalsHumansChannel blockerReceptorNeuroinflammationMice KnockoutKv1.3 Potassium ChannelGlutamate secretionChemistryGlutaminaseCell adhesion moleculeIntegrin beta1Glutamate receptorGeneral MedicineCell biologyGlutamine030104 developmental biology030220 oncology & carcinogenesisTh17 CellsSNARE ProteinsResearch ArticleSignal Transduction
researchProduct

Impact of dietary intervention on serum neurofilament light chain in multiple sclerosis

2021

Background and ObjectivesAdapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative therapeutic strategies for multiple sclerosis (MS), but information on their impact on neuroaxonal damage is lacking. Thus, we explored the impact of diets on serum neurofilament light chain (sNfL) levels in patients with relapsing-remitting MS.MethodsWe retrospectively evaluated a prospective randomized controlled trial of 60 patients with MS who were on a common diet or ketogenic diet or fasting. We examined sNfL levels of 40 participants at baseline and at the end of the study after 6 months using single molecule array assay.ResultssNfL levels were investigated in 9 contr…

OncologyAdultMalemedicine.medical_specialty2041medicine.medical_treatmentNeurofilament lightArticlelaw.inventionMultiple Sclerosis Relapsing-RemittingRandomized controlled triallawNeurofilament ProteinsInternal medicineOutcome Assessment Health CareMedicineHumansProspective StudiesTrial registrationSingle cycleCaloric RestrictionRetrospective Studiesbusiness.industryMultiple sclerosisFastingMiddle Agedmedicine.disease322Clinical trialNeurologyMultiple sclerosis functional compositeFemaleNeurology (clinical)businessDiet KetogenicFunction and Dysfunction of the Nervous SystemKetogenic diet
researchProduct

Genome-wide significant association with seven novel multiple sclerosis risk loci

2015

Objective A recent large-scale study in multiple sclerosis (MS) using the ImmunoChip platform reported on 11 loci that showed suggestive genetic association with MS. Additional data in sufficiently sized and independent data sets are needed to assess whether these loci represent genuine MS risk factors. Methods The lead SNPs of all 11 loci were genotyped in 10 796 MS cases and 10 793 controls from Germany, Spain, France, the Netherlands, Austria and Russia, that were independent from the previously reported cohorts. Association analyses were performed using logistic regression based on an additive model. Summary effect size estimates were calculated using fixed-effect meta-analysis. Results…

GeneticsMultiple SclerosisMultiple sclerosisCase-control studySingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologymedicine.diseaseLogistic regressionPolymorphism Single NucleotideGene FrequencyGenetic LociRisk FactorsCase-Control StudiesGeneticsmedicineHumansGenetic Predisposition to DiseaseAllele frequencyGenetics (clinical)Genome-Wide Association StudyGenetic association
researchProduct

NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke

2019

Background and Purpose— Ischemic stroke causes major disability as a consequence of neuronal loss and recurrent ischemic events. Biomarkers predicting tissue damage or stroke recurrence might be useful to guide an individualized stroke therapy. NfL (neurofilament light chain) is a promising biomarker that might be used for this purpose. Methods— We used individual data of patients with an acute ischemic stroke and clinical long term follow-up. Serum NfL (sNfL) was quantified within 24 hours after admission and after 1 year and compared with other biomarkers (GDF15 [growth differentiation factor 15], S100, NT-proBNP [N-terminal pro-B-type natriuretic peptide], ANP [atrial natriuretic peptid…

Advanced and Specialized Nursing0303 health sciencesmedicine.medical_specialtybusiness.industrymedicine.drug_classOdds ratiomedicine.disease3. Good healthBrain ischemia03 medical and health sciences0302 clinical medicineInterquartile rangeModified Rankin ScaleInternal medicineDiabetes mellitusClinical endpointmedicineNatriuretic peptideCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke030217 neurology & neurosurgery030304 developmental biologyStroke
researchProduct

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

2019

Background: The course of multiple sclerosis (MS) shows substantial inter-individual variability. The underlying determinants of disease severity likely involve genetic and environmental factors. Objective: The aim of this study was to assess the impact of APOE and HLA polymorphisms as well as smoking and body mass index (BMI) in the very early MS course. Methods: Untreated patients ( n = 263) with a recent diagnosis of relapsing-remitting (RR) MS or clinically isolated syndrome underwent standardized magnetic resonance imaging (MRI). Genotyping was performed for single-nucleotide polymorphisms (SNPs) rs3135388 tagging the HLA-DRB1*15:01 haplotype and rs7412 (Ɛ2) and rs429358 (Ɛ4) in APOE. …

AdultMaleApolipoprotein EMultiple SclerosisAdolescentPolymorphism Single NucleotideBody Mass IndexYoung Adult03 medical and health sciencesApolipoproteins E0302 clinical medicineAtrophyMedizinische FakultätmedicineHumansSNPGenetic Predisposition to Disease030212 general & internal medicineddc:610Risk factorHLA-DRB1Agedbusiness.industryMultiple sclerosisSmokingNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyImmunologyFemaleNeurology (clinical)AtrophybusinessBody mass index030217 neurology & neurosurgeryHLA-DRB1 Chains
researchProduct

How to treat tumefactive demyelinating disease?

2013

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially showed a good response to steroid treatment, with full clinical recovery. However, after relapse of…

Malemedicine.medical_specialtyPathologyTime FactorsBiopsymedicine.medical_treatmentDrug Administration ScheduleLesionRecurrenceInduction therapyBiopsymedicineDemyelinating diseaseHumansIn patientmedicine.diagnostic_testDrug Substitutionbusiness.industryMultiple sclerosisImmunosuppressionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegimenTreatment OutcomeNeurologyDrug Therapy CombinationSteroidsNeurology (clinical)Radiologymedicine.symptombusinessImmunosuppressive AgentsDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement

2020

Background As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. Objective We aimed to assess the spectrum and intake frequency of supplementary medication in a cohort of MS patients and to analyse the effect of biotin intake on measurement of serum neurofilament light chain (sNfL), an emerging marker of disease activity. Methods MS patients visiting our neurology outpatient clinic completed a questionnaire on their past or present use of vitamins or dietary supplements. In addition, the impact of two different doses of …

0301 basic medicinebusiness.industryMultiple sclerosisNeurofilament lightvitamin DvitaminsInterference (genetic)medicine.diseaseBioinformaticsOriginal Research PaperMultiple sclerosisdietary supplements03 medical and health sciencesCellular and Molecular Neuroscience030104 developmental biology0302 clinical medicinebiotinmedicineVitamin D and neurologyNeurology (clinical)Medical prescriptionbusiness030217 neurology & neurosurgeryMultiple Sclerosis Journal - Experimental, Translational and Clinical
researchProduct

Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus

2021

Background: The aim was to evaluate the diagnostic potential of serum neurofilament light chain (sNfL) measurements in patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Methods: sNfL levels were determined by single molecule array assay in a retrospective cross-sectional cohort of 144 patients with systemic lupus erythematosus (SLE). After log-transformation of sNfL levels, mean sNfL levels were compared between NPSLE patients and SLE patients without neuropsychiatric disease using Student’s t test. Furthermore, the association of different neuropsychiatric manifestations with sNfL levels was assessed using a one-way analysis of variance (ANOVA) with post hoc analysis. As…

medicine.medical_specialtyNeurofilament lightCentral nervous systemGastroenterologychemistry.chemical_compoundInternal medicinePost-hoc analysismedicineRC346-429Original ResearchPharmacologyCreatininebusiness.industrymedicine.anatomical_structureneurofilament light chainNeurologychemistryCohortBiomarker (medicine)biomarkerMultiple linear regression analysisNeurology (clinical)Neurology. Diseases of the nervous systemCNSbusinessNeuropsychiatric diseaseneurolupusNPSLETherapeutic Advances in Neurological Disorders
researchProduct

Microgravity-induced alterations in signal transduction in cells of the immune system

2010

Since decades it is known that the activity of cells of the immune system is severely dysregulated in microgravity, however, the underlying molecular aspects have not been elucidated yet. The identification of gravity-sensitive molecular mechanisms in cells of the immune system is an important and indispensable prerequisite for the development of counteractive measures to prevent or treat disturbed immune cell function of astronauts during long-term space missions. Moreover, their sensitivity to altered gravity renders immune cells an ideal model system to understand if and how gravity on Earth is required for normal mammalian cell function and signal transduction. We investigated the effec…

Innate immunityICAM-1Innate immune system10017 Institute of AnatomyChemistryAdaptive immunityAerospace Engineering610 Medicine & healthSpaceflightSignal transductionAcquired immune systemJurkat cellsCell biologyGravisensitivityImmune system2202 Aerospace EngineeringCell culture570 Life sciences; biologySignal transductionClinostatActa Astronautica
researchProduct

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

CCR7 on CD4+ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis

2018

Abstract Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the CNS. Myelin-specific CD4+ Th lymphocytes are known to play a major role in both MS and its animal model experimental autoimmune encephalomyelitis (EAE). CCR7 is a critical element for immune cell trafficking and recirculation, that is, lymph node homing, under homeostatic conditions; blocking CCR7+ central memory cells from egress of lymph nodes is a therapeutic approach in MS. To define the effect of CD4+ T cell–specific constitutive deletion of CCR7 in the priming and effector phase in EAE, we used an active EAE approach in T cell reconstituted Rag1−/− mice, as well as adoptive transfer E…

0301 basic medicineAdoptive cell transferChemistryEncephalomyelitisT cellImmunologyExperimental autoimmune encephalomyelitisPriming (immunology)chemical and pharmacologic phenomenahemic and immune systemsmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmune systemAntigenimmune system diseasesImmunologymedicineImmunology and AllergytissuesNeuroinflammation030215 immunologyThe Journal of Immunology
researchProduct

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity

2021

Abstract Dimethyl fumarate, an approved treatment for relapsing-remitting multiple sclerosis, exerts pleiotropic effects on immune cells as well as CNS resident cells. Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profile of human CD4+ as well as CD8+ T cells and restricts their antioxidative capacities by decreasing intracellular levels of the reactive oxygen species scavenger glutathione. This causes an increase in mitochondrial reactive oxygen species levels accompanied by an enhanced mitochondrial stress response, ultimately leading to impaired mitochondrial function. Enhanced mitochondrial reactive oxygen species levels not only result in enhanced T…

AdultCD4-Positive T-LymphocytesMaleDimethyl FumarateT cellAutoimmunityCD8-Positive T-Lymphocytesmedicine.disease_causeAntioxidantsCohort StudiesMiceYoung Adultchemistry.chemical_compoundMultiple Sclerosis Relapsing-RemittingImmune systemmedicineAnimalsHumanschemistry.chemical_classificationReactive oxygen speciesDimethyl fumarateExperimental autoimmune encephalomyelitisGlutathioneMiddle Agedmedicine.diseaseCell biologyMice Inbred C57BLmedicine.anatomical_structurechemistryFemaleNeurology (clinical)Immunosuppressive AgentsOxidative stressCD8Brain
researchProduct

IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments.

2014

Multiple sclerosis (MS), an autoimmune neurological disorder, is driven by self-reactive T helper (Th) cells. Research on the role of Th17 lymphocytes in MS pathogenesis has made significant progress in identifying various immunological as well as environmental factors that induce the differentiation and expansion of these cells, different subsets of Th17 cells with varying degrees of pathogenicity, and the role of the secreted effector cytokines. While approved therapies for MS offer significant benefit to patients, there remain unmet needs. Ongoing clinical trials aim to translate the advanced knowledge of Th17 cytokines to improved therapies. This review discusses the current status and …

Central Nervous SystemPathologymedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyAutoimmunityNeurological disorderGeneral Biochemistry Genetics and Molecular BiologyUnmet needsPathogenesisMicemedicineImmunology and AllergyAnimalsHumansEffectorbusiness.industryMultiple sclerosisInterleukin-17Cell DifferentiationImmunotherapyInterferon-betamedicine.diseaseClinical trialImmunologyTh17 CellsInterleukin 17ImmunotherapyInflammation MediatorsbusinessCytokinegrowth factor reviews
researchProduct

Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?

2016

Prevention of progression in neurological diseases, particularly in multiple sclerosis (MS) but also in neurodegenerative diseases, remains a significant challenge. MS patients switch from a relapsing-remitting to a progressive disease course, but it is not understood why and how this conversion occurs and why some patients never experience disease progression. Do aging and accumulation of neuronal damage induce progression, or do cognitive symptoms and accelerated grey matter (GM) atrophy point to distinct processes affecting networks? This review weighs accepted dogma against real data on the secondary progressive phase of the disease, highlighting current challenges in this important fie…

0301 basic medicineSenescencePathologymedicine.medical_specialtyMultiple SclerosisDiseaseGrey matter03 medical and health sciences0302 clinical medicineAtrophymedicineHumansSecondary progressiveNeuronsbusiness.industryGeneral NeuroscienceMultiple sclerosisNeurodegenerationBrainmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologymedicine.anatomical_structureDisease ProgressionbusinessNeuroscience030217 neurology & neurosurgeryProgressive diseaseTrends in Neurosciences
researchProduct

Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS

2020

ObjectiveWe applied longitudinal 3T MRI and advanced computational models in 2 independent cohorts of patients with early MS to investigate how white matter (WM) lesion distribution and cortical atrophy topographically interrelate and affect functional disability.MethodsClinical disability was measured using the Expanded Disability Status Scale Score at baseline and at 1-year follow-up in a cohort of 119 patients with early relapsing-remitting MS and in a replication cohort of 81 patients. Covarying patterns of cortical atrophy and baseline lesion distribution were extracted by parallel independent component analysis. Predictive power of covarying patterns for disability progression was tes…

OncologyAdultMalemedicine.medical_specialtySupport Vector Machine41Article312LesionWhite matterText miningMultiple Sclerosis Relapsing-RemittingInternal medicineCerebellumMedicineHumansLongitudinal StudiesCerebral CortexExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingWhite MatterHyperintensitymedicine.anatomical_structureNeurologyCohortDisease ProgressionFemaleNeurology (clinical)medicine.symptomAtrophybusinessNeurology® Neuroimmunology & Neuroinflammation
researchProduct

Inhibiting ERK nuclear translocation in Th17 cells leads to downregulation of GM-CSF

2014

MAPK/ERK pathwayNeurologyDownregulation and upregulationImmunologyImmunology and AllergyNeurology (clinical)Nuclear translocationCell biologyJournal of Neuroimmunology
researchProduct

The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis

2016

Purpose: In secondary progressive Multiple Sclerosis (SPMS), global neurodegeneration as a driver of disability gains importance in comparison to focal inflammatory processes. However, clinical MRI does not visualize changes of tissue composition outside MS lesions. This quantitative MRI (qMRI) study investigated cortical and deep gray matter (GM) proton density (PD) values and T1 relaxation times to explore their potential to assess neuronal damage and its relationship to clinical disability in SPMS. Materials and Methods: 11 SPMS patients underwent quantitative T1 and PD mapping. Parameter values across the cerebral cortex and deep GM structures were compared with 11 healthy controls, and…

Central Nervous SystemMalePathologyPhysiologylcsh:MedicinePathology and Laboratory MedicineNervous SystemBrain mappingDiagnostic Radiology030218 nuclear medicine & medical imaging0302 clinical medicineThalamusMedicine and Health SciencesRelaxation TimeMedicineGray Matterlcsh:ScienceCerebrospinal FluidCerebral CortexMultidisciplinarymedicine.diagnostic_testRadiology and ImagingPhysicsPutamenNeurodegenerationBrainNeurodegenerative DiseasesMultiple Sclerosis Chronic ProgressiveMagnetic Resonance ImagingBody Fluidsmedicine.anatomical_structureNeurologyCerebral cortexPhysical SciencesFemaleAnatomyResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisImaging TechniquesImmunologyCentral nervous systemThalamusResearch and Analysis MethodsAutoimmune Diseases03 medical and health sciencesSigns and SymptomsDiagnostic MedicineIntellectual DisabilityHumansddc:610Relaxation (Physics)business.industryMultiple sclerosislcsh:RBiology and Life SciencesMagnetic resonance imagingmedicine.diseaseDemyelinating DisordersCase-Control StudiesLesionslcsh:QClinical ImmunologyClinical Medicinebusiness030217 neurology & neurosurgeryPLOS ONE
researchProduct

Neuronal injury in chronic CNS inflammation.

2010

Introduction Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system which is characterized by inflammatory demyelination and neurodegeneration. Neurological symptoms include sensory disturbances, optic neuritis, limb weakness, ataxia, bladder dysfunction, cognitive deficits and fatigue. Pathophysiology The inflammation process with MS is promoted by several inflammatory cytokines produced by the immune cells themselves and local resident cells like activated microglia. Consecutive damaging pathways involve the transmigration of activated B lymphocytes and plasma cells, which synthesize antibodies against the myelin sheath, boost the immune atta…

Multiple SclerosisInflammationNeuroprotectionSeverity of Illness IndexProinflammatory cytokineCentral Nervous System DiseasesmedicineAnimalsHumansRemyelinationNeuroinflammationInflammationNeuronsMicrogliabusiness.industryMultiple sclerosismedicine.diseaseAstrogliosisAnesthesiology and Pain Medicinemedicine.anatomical_structureNeuroprotective AgentsImmunologyChronic DiseaseMicrogliamedicine.symptomInflammation MediatorsbusinessBest practiceresearch. Clinical anaesthesiology
researchProduct

Treatment choices and neuropsychological symptoms of a large cohort of early MS

2018

ObjectiveTo assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS.MethodsThe German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms.ResultsOf 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06–40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded …

medicine.medical_specialty41610 Medicine & healthArticle03 medical and health sciences0302 clinical medicineQuality of lifeInterquartile rangeInternal medicinemedicineddc:610030212 general & internal medicine10. No inequalityDepression (differential diagnoses)Expanded Disability Status ScaleClinically isolated syndromebusiness.industryMultiple sclerosisNeuropsychologymedicine.disease3. Good healthNeurologyCohortNeurology (clinical)businessFunction and Dysfunction of the Nervous System030217 neurology & neurosurgery
researchProduct

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

2017

ObjectiveTo determine the factors that influence B-cell repopulation after B-cell depletion therapy in neurologic patients and derive recommendations for monitoring and dosing of patients.MethodsIn this study, we determined the association of body surface area (BSA; calculated by body weight and height with the Dubois formula), sex, pretreatment therapy, age, CSF data, and white blood cell counts with the risk and timing of B-cell repopulation, defined as 1% CD19+ cells (of total lymphocytes), following 87 B cell–depleting anti-CD20 treatment cycles of 45 neurologic patients (28 women; mean age ± SD, 44.5 ± 15.0 years).ResultsPatients with a larger BSA had a higher probability to reach 1% C…

0301 basic medicine40medicine.medical_specialty41132LymphocyteUrologyCD19Article03 medical and health sciences0302 clinical medicineWhite blood cellMedicineDosingAdverse effectB cellBody surface areabiologybusiness.industry14323030104 developmental biologymedicine.anatomical_structureNeurologybiology.proteinRepopulationNeurology (clinical)business030217 neurology & neurosurgeryNeurology(R) neuroimmunologyneuroinflammation
researchProduct

CNS-localized myeloid cells capture living invading T cells during neuroinflammation

2020

Using an in vivo real-time approach, the authors show that local myeloid cells remove early CNS-invading T cells via an engulfment pathway that is dependent on N-acetyl-D-glucosamine (GlcNAc) and lectin. These results reveal a novel capacity of myeloid cells to counteract neuroinflammation.

0301 basic medicineCentral Nervous SystemProgrammed cell deathCell signalingEncephalomyelitis Autoimmune ExperimentalCell SurvivalEncephalomyelitisT cellT-LymphocytesImmunologyInnate Immunity and InflammationCX3C Chemokine Receptor 1AutoimmunityReceptors Cell SurfaceCell CommunicationPhosphatidylserinesBiologyLymphocyte ActivationSeverity of Illness IndexArticle03 medical and health sciencesMice0302 clinical medicineNeuroinflammationPhagocytosisIn vivomedicineImmunology and AllergyAnimalsLectins C-TypeMyeloid CellsNeuroinflammationInflammationGlucosamineCell DeathExperimental autoimmune encephalomyelitismedicine.diseaseCell biology030104 developmental biologymedicine.anatomical_structureMannose-Binding LectinsTh17 Cells030217 neurology & neurosurgeryEx vivoMannose ReceptorThe Journal of Experimental Medicine
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Low frequency and rare coding variation contributes to multiple sclerosis risk

2018

AbstractMultiple sclerosis is a common, complex neurological disease, where almost 20% of risk heritability can be attributed to common genetic variants, including &gt;230 identified by genome-wide association studies (Patsopoulos et al., 2017). Multiple strands of evidence suggest that the majority of the remaining heritability is also due to the additive effects of individual variants, rather than epistatic interactions between these variants, or mutations exclusive to individual families. Here, we show in 68,379 cases and controls that as much as 5% of this heritability is explained by low-frequency variation in gene coding sequence. We identify four novel genes driving MS risk independe…

Genetics0303 health sciencesLinkage disequilibriumMultiple sclerosisDiseaseBiologyHeritabilitymedicine.disease3. Good health03 medical and health sciences0302 clinical medicinemedicineEpistasisCoding regionGene030217 neurology & neurosurgery030304 developmental biologyGenetic association
researchProduct

The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility

2017

Abstract:We assembled and analyzed genetic data of 47,351 multiple sclerosis (MS) subjects and 68,284 control subjects and establish a reference map of the genetic architecture of MS that includes 200 autosomal susceptibility variants outside the major histocompatibility complex (MHC), one chromosome X variant, and 32 independent associations within the extended MHC. We used an ensemble of methods to prioritize up to 551 potentially associated MS susceptibility genes, that implicate multiple innate and adaptive pathways distributed across the cellular components of the immune system. Using expression profiles from purified human microglia, we do find enrichment for MS genes in these brain -…

0303 health sciencesMicrogliaMultiple sclerosisCentral nervous systemBiologymedicine.diseaseMajor histocompatibility complex03 medical and health sciences0302 clinical medicineImmune systemmedicine.anatomical_structureAutoimmune ProcessImmunologymedicinebiology.proteinGene030217 neurology & neurosurgeryX chromosome030304 developmental biology
researchProduct

A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes

2010

Recent findings suggest that neuronal pathology occurs early in the course of multiple sclerosis and seems to be responsible for accumulation of disability. Nonetheless, the nervous system has an intrinsic potential for repair and compensation in the neuronal component. Disease-modifying drugs such as glatiramer acetate interfere with, and down-regulate, inflammatory pathology and slow neurodegeneration. Moreover, certain regulatory cytokines and neurotrophic factors have the capacity to promote neuronal and axonal repair. Given the importance of neuronal injury in multiple sclerosis and the potential of certain treatments for neuronal repair, it is important to possess adequate and sensiti…

medicine.medical_specialtyPathologyMultiple SclerosisNeuroprotectionNeurotrophic factorsmedicineHumansGlatiramer acetateNeuronsmedicine.diagnostic_testbusiness.industryMultiple sclerosisNeurodegenerationBrainMagnetic resonance imagingAnatomical pathologymedicine.diseaseMagnetic Resonance ImagingAxonsnervous systemNeurologyNeurology (clinical)businessNeuroscienceDiffusion MRImedicine.drugJournal of the Neurological Sciences
researchProduct

Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis

2021

Background: Serum neurofilament light chain (sNfL) is a promising biomarker to complement the decision-making process in multiple sclerosis (MS) patients. However, although sNfL levels are able to detect disease activity and to predict future disability, the growing evidence has not yet been translated into practicable recommendations for an implementation into clinical routine. Methods: The observation of a patient with extensive inflammatory activity in magnetic resonance imaging (MRI) along with an extremely high sNfL level in the absence of any clinical symptoms prompted us to investigate common characteristics of our MS patients with the highest sNfL levels in a retrospective cohort st…

Pharmacologybusiness.industrysubclinical disease activityNeurofilament lightMultiple sclerosismultiple sclerosismedicine.diseaseextreme levels03 medical and health sciencesneurofilament light chain0302 clinical medicineNeurologyImmunologymedicinebiomarkerBiomarker (medicine)Neurology. Diseases of the nervous system030212 general & internal medicineNeurology (clinical)RC346-429business030217 neurology & neurosurgeryOriginal ResearchTherapeutic Advances in Neurological Disorders
researchProduct

Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody–positive autoimmune encephalitis under imm…

2020

Neurological immune-mediated side effects are rare but often severe complications of immune checkpoint inhibitor (ICI) treatment. This report describes a severe case of nivolumab/ipilimumab-associated glutamic acid decarboxylase 65-positive autoimmune encephalitis. It proposes neurofilament light chain levels, a biomarker indicating axonal damage, in the cerebrospinal fluid and serum as a putative novel biomarker for this diagnostically and therapeutically challenging entity with an often unfavorable outcome. Additionally, we provide an overview of previous reports of patients developing autoimmune encephalitis under ICI treatment.

NeurofilamentGlutamate decarboxylaseIntermediate Filaments610 MedizinHashimoto Disease03 medical and health sciences0302 clinical medicineCerebrospinal fluid610 Medical sciencesHumansMedicine030212 general & internal medicineImmune Checkpoint InhibitorsAutoimmune encephalitisbiologyGlutamate Decarboxylasebusiness.industrymedicine.diseaseIpilimumabNivolumabNeurologyImmunologybiology.proteinEncephalitisBiomarker (medicine)Neurology (clinical)AntibodyNivolumabbusiness030217 neurology & neurosurgeryEncephalitisEuropean Journal of Neurology
researchProduct

Graph Theoretical Framework of Brain Networks in Multiple Sclerosis: A Review of Concepts.

2019

Abstract Network science provides powerful access to essential organizational principles of the human brain. It has been applied in combination with graph theory to characterize brain connectivity patterns. In multiple sclerosis (MS), analysis of the brain networks derived from either structural or functional imaging provides new insights into pathological processes within the gray and white matter. Beyond focal lesions and diffuse tissue damage, network connectivity patterns could be important for closely tracking and predicting the disease course. In this review, we describe concepts of graph theory, highlight novel issues of tissue reorganization in acute and chronic neuroinflammation an…

0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisModels NeurologicalNetwork science03 medical and health sciences0302 clinical medicineNeural PathwaysmedicineAnimalsHumansGeneral NeuroscienceMultiple sclerosisBrainGraph theoryHuman brainmedicine.diseaseFunctional imaging030104 developmental biologymedicine.anatomical_structureGraph (abstract data type)DisconnectionPsychologyNeuroscience030217 neurology & neurosurgeryNetwork analysisNeuroscience
researchProduct

Gatekeeper role of brain antigen‐presenting CD11c + cells in neuroinflammation

2015

Multiple sclerosis is the most frequent chronic inflammatory disease of the CNS. The entry and survival of pathogenic T cells in the CNS are crucial for the initiation and persistence of autoimmune neuroinflammation. In this respect, contradictory evidence exists on the role of the most potent type of antigen-presenting cells, dendritic cells. Applying intravital two-photon microscopy, we demonstrate the gatekeeper function of CNS professional antigen-presenting CD11c(+) cells, which preferentially interact with Th17 cells. IL-17 expression correlates with expression of GM-CSF by T cells and with accumulation of CNS CD11c(+) cells. These CD11c(+) cells are organized in perivascular clusters…

0301 basic medicineEncephalomyelitis Autoimmune ExperimentalT-LymphocytesAntigen-Presenting CellsGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInterleukin 210302 clinical medicineCell MovementAnimalsCytotoxic T cellAntigen-presenting cellMolecular BiologyNeuroinflammationInterleukin 3CD40General Immunology and MicrobiologybiologyGeneral NeuroscienceInterleukin-17BrainGranulocyte-Macrophage Colony-Stimulating Factorhemic and immune systemsDendritic CellsArticlesNatural killer T cellCD11c AntigenMice Inbred C57BL030104 developmental biologyImmunologyInterleukin 12biology.proteinTh17 Cells030215 immunologyThe EMBO Journal
researchProduct

Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo

2014

The quality of the adaptive immune response depends on the differentiation of distinct CD4(+) helper T cell subsets, and the magnitude of an immune response is controlled by CD4(+)Foxp3(+) regulatory T cells (Treg cells). However, how a tissue- and cell type-specific suppressor program of Treg cells is mechanistically orchestrated has remained largely unexplored. Through the use of Treg cell-specific gene targeting, we found that the suppression of allergic immune responses in the lungs mediated by T helper type 2 (TH2) cells was dependent on the activity of the protein kinase CK2. Genetic ablation of the β-subunit of CK2 specifically in Treg cells resulted in the proliferation of a hithert…

CD4-Positive T-LymphocytesMaleT cellImmunologyMice TransgenicReceptors Cell Surfacechemical and pharmacologic phenomenaCell Growth ProcessesT-Lymphocytes RegulatoryCell LineMiceTh2 CellsImmune systemHypersensitivitymedicineAnimalsHumansImmunology and AllergyIL-2 receptorCasein Kinase IIMice Inbred BALB CChemistryPeripheral toleranceFOXP3Cell DifferentiationForkhead Transcription FactorsDendritic CellsAcquired immune systemCell biologyMice Inbred C57BLmedicine.anatomical_structureCell cultureInterferon Regulatory FactorsImmunologyLeukocytes MononuclearIRF4Nature Immunology
researchProduct

The role of CD8+ T cells and their local interaction with CD4+ T cells in myelin oligodendrocyte glycoprotein35-55-induced experimental autoimmune en…

2013

Abstract T cells have an essential role in the induction of multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE). Although for CD4+ T cells it is well established that they contribute to the disease, less is known about the role of CD8+ T cells. Our aim was to determine the individual contribution of CD4+ and CD8+ T cells in myelin oligodendrocyte glycoprotein (MOG)35–55–induced EAE. We investigated MOG35–55–activated CD8+ T cells to clarify their potential to induce or attenuate EAE. We monitored the behavior of CD8+ T cells and their interaction with CD4+ T cells directly at the site of inflammation in the CNS using intravital imaging of the brainstem of…

CD4-Positive T-LymphocytesCentral Nervous SystemEncephalomyelitis Autoimmune ExperimentalT cellImmunologyMedizinCell CommunicationCD8-Positive T-LymphocytesLymphocyte ActivationInterleukin 21MiceCell MovementmedicineImmunology and AllergyCytotoxic T cellAnimalsIL-2 receptorInflammationMice KnockoutCD40biologyCD28Molecular biologyPeptide FragmentsMice Inbred C57BLmedicine.anatomical_structureImmunologybiology.proteinInterleukin 12Myelin-Oligodendrocyte GlycoproteinCD8Journal of immunology (Baltimore, Md. : 1950)
researchProduct

Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.

2015

Background: Multiple sclerosis is a chronic inflammatory central nervous system disease diagnosed by clinical presentation and characteristic magnetic resonance imaging findings. The role of cerebrospinal fluid (CSF) analysis has been emphasized in particular in the context of differential diagnosis in patients with a first episode suggestive of multiple sclerosis. Objective: We investigated here the potential additional value of analysis of CSF cellularity by fluorescence activated cell sorting (FACS) in the setting of a routine diagnostic work-up in our inpatient clinic. Methods: CSF cells from back-up samples from patients with suspected chronic inflammatory central nervous system disord…

0301 basic medicineCD4-Positive T-LymphocytesMalePathologyTime FactorsLipopolysaccharide ReceptorsCell SeparationCD8-Positive T-LymphocytesMonocytes0302 clinical medicineCerebrospinal fluidCerebrospinal FluidClinically isolated syndromemedicine.diagnostic_testMiddle AgedFlow CytometryPrognosisMagnetic Resonance Imagingmedicine.anatomical_structurePhenotypeNeurologyDisease ProgressionFemaleAdultmedicine.medical_specialtyMultiple SclerosisAdolescentT cellImmunophenotypingCentral nervous system disease03 medical and health sciencesYoung AdultPredictive Value of TestsmedicineHumansB cellAgedbusiness.industryMonocyteMultiple sclerosisOligoclonal BandsMagnetic resonance imagingmedicine.diseaseAntigens CD20030104 developmental biologyImmunologyNeurology (clinical)business030217 neurology & neurosurgeryBiomarkersDemyelinating DiseasesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Two laboratory-confirmed cases of Japanese encephalitis imported to Germany by travelers returning from Southeast Asia

2011

Japanese encephalitis virus is the leading cause of encephalitis in Asia and parts of the Pacific. Despite the high number of symptomatic infections in endemic countries, clinical disease in travelers is rare. However, an increasing number of imported infections from popular holiday destinations in Southeast Asia have been recorded in the past few years, including serious disease courses in short-term travelers. Here we report two severe, non-fatal cases in tourists, who returned from a long-time stay in Thailand and a short-term trip to Bali, Indonesia, respectively. Recommendations for vaccination and pre-travel advice are discussed.

MaleVeterinary medicineDestinationsAntibodies ViralSoutheast asiaGermanyVirologyHumansMedicineEncephalitis JapaneseSocioeconomicsAgedTravelbiologybusiness.industryMiddle AgedJapanese encephalitisThailandbiology.organism_classificationClinical diseasemedicine.diseaseVaccinationFlavivirusInfectious DiseasesImmunoglobulin MIndonesiaImmunoglobulin GFemalebusinesshuman activitiesEncephalitisJournal of Clinical Virology
researchProduct

The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multipl…

2020

The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 &times

Signal peptideGene isoformSignal peptidePopulationSingle-nucleotide polymorphismLocus (genetics)610 Medicine & healthBiologymultiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineSNPIL-22 binding protein isoformsignal peptideddc:610Alleleeducation610 Medicine &amp; healthlcsh:QH301-705.5Peptide sequence030304 developmental biology0303 health scienceseducation.field_of_studyautoimmuneGeneral MedicineMolecular biologylcsh:Biology (General)<i>IL22RA2</i>IL22RA2Mutation[SDV.IMM]Life Sciences [q-bio]/Immunologymutation030217 neurology & neurosurgeryAutoimmune
researchProduct

EGFL7 - a potential therapeutic target for multiple sclerosis?

2018

0301 basic medicineEGF Family of ProteinsMultiple SclerosisClinical BiochemistryEndothelial Growth FactorsBlood–brain barrier03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicineAnimalsHumansMolecular Targeted TherapyPharmacologybusiness.industryMultiple sclerosisNatalizumabCalcium-Binding Proteinsmedicine.disease030104 developmental biologymedicine.anatomical_structureBlood-Brain BarrierMolecular MedicineEGFL7businessNeuroscience030217 neurology & neurosurgeryExpert opinion on therapeutic targets
researchProduct

A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis

2017

Background: The role of cortical lesions (CLs) in disease progression and clinical deficits is increasingly recognized in multiple sclerosis (MS); however the origin of CLs in MS still remains unclear. Objective: Here, we report a para-sulcal CL detected two years after diagnosis in a relapsing-remitting MS (RRMS) patient without manifestation of clinical deficit. Methods: Ultra-high field (7T) MR imaging using magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE) sequence was performed. Results: A para-sulcal CL was detected which showed hypointense rim and iso- to hyperintense core. This was detected in the proximity of the leptomeninges in the left precentral gyrus extendi…

0301 basic medicinePathologymedicine.medical_specialty7TLesionMultiple sclerosis03 medical and health sciencesMeningeal inflammation0302 clinical medicineCLs upper limitsIn vivoatypical cortical lesionsmedicinemagnetic resonance imagingCORTICAL DEMYELINATIONmedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionMagnetic resonance imagingmedicine.disease030104 developmental biologyNeurologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Enhanced network activity despite clinical recovery in experimental neuroinflammation using two-photon calcium imaging

2014

Calcium imagingNeurologyTwo-photon excitation microscopyChemistryImmunologyImmunology and AllergyNeurology (clinical)NeuroscienceNetwork activityNeuroinflammationJournal of Neuroimmunology
researchProduct

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci

2010

A recent meta-analysis identified seven single-nucleotide polymorphisms (SNPs) with suggestive evidence of association with multiple sclerosis (MS). We report an analysis of these polymorphisms in a replication study that includes 8,085 cases and 7,777 controls. A meta-analysis across the replication collections and a joint analysis with the discovery data set were performed. The possible functional consequences of the validated susceptibility loci were explored using RNA expression data. For all of the tested SNPs, the effect observed in the replication phase involved the same allele and the same direction of effect observed in the discovery phase. Three loci exceeded genome-wide significa…

Multiple SclerosisImmunologyGenome-wide association studyLocus (genetics)Single-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticleInterleukin-12 Subunit p35Cell Line03 medical and health sciences0302 clinical medicineIL12AGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleGenetics (clinical)Cell Proliferation030304 developmental biologyGenetics0303 health sciencesTumor Suppressor ProteinsMultiple sclerosisCell cyclemedicine.disease3. Good healthCeliac DiseaseCase-Control StudiesImmunologyExpression quantitative trait lociLeukocytes MononuclearRGS Proteins030217 neurology & neurosurgeryGenes &amp; Immunity
researchProduct

A human post-mortem brain model for the standardization of multi-centre MRI studies

2015

Multi-centre MRI studies of the brain are essential for enrolling large and diverse patient cohorts, as required for the investigation of heterogeneous neurological and psychiatric diseases. However, the multi-site comparison of standard MRI data sets that are weighted with respect to tissue parameters such as the relaxation times (T1, T2) and proton density (PD) may be problematic, as signal intensities and image contrasts depend on site-specific details such as the sequences used, imaging parameters, and sensitivity profiles of the radiofrequency (RF) coils. Water or gel phantoms are frequently used for long-term and/or inter-site quality assessment. However, these phantoms hardly mimic t…

Models Anatomicmedicine.medical_specialtyNeurologyCognitive NeuroscienceModels NeurologicalMulti-centre MRI studies; Post-mortem brain; Quantitative MRI; Standardization; Aged; Artifacts; Brain; Female; Humans; Magnetic Resonance Imaging; Multicenter Studies as Topic; Phantoms Imaging; Reproducibility of Results; Models Anatomic; Models Neurological; Postmortem Changes; Cognitive Neuroscience; Neurology; Medicine (all)Cognitive neuroscienceImaging phantomPhantomsImagingWhite matterModelsPost-mortem brainmedicineHumansMulticenter Studies as TopicMagnetization transferMulti-centre MRI studiesAgedmedicine.diagnostic_testbusiness.industryPhantoms ImagingMedicine (all)AnatomicBrainReproducibility of ResultsMagnetic resonance imagingHuman brainQuantitative MRIMagnetic Resonance ImagingStandardizationmedicine.anatomical_structureNeurologyPostmortem ChangesNeurologicalFemaleBrainstemNuclear medicinebusinessArtifacts
researchProduct

Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose

2012

Vor dem Hintergrund der Verfugbarkeit neuer, hochwirksamer MS-Therapeutika und der besonderen Bedeutung des fruhen Krankheitsverlaufs fur die Prognose der MS kommt der Definition von Therapiezielen starkere Bedeutung zu. Insbesondere die Erstellung von Kriterien fur eine rechtzeitige Eskalationstherapie bei MS-Patienten ist eine relevante Frage der alltaglichen Versorgung. Leider fehlen fur diese Fragestellung Studienergebnisse mit Klasse-I-Evidenz. Im Rahmen eines industrieunterstutzten Expertenmeetings wurden Therapieziele von immunmodulatorischen Basis- und Eskalationstherapien fur Patienten mit schubformig-remittierender MS und Kriterien fur die rechtzeitige Umstellung auf Eskalationsth…

Gynecologymedicine.medical_specialtybusiness.industrymedicineNeurology (clinical)businessMultiple skleroseAktuelle Neurologie
researchProduct

Neurons as targets for T cells in the nervous system

2013

International audience; Accumulating evidence shows that T cells penetrate the central nervous system (CNS) parenchyma in several autoimmune, infectious, and degenerative neurological diseases. The structural and functional consequences for CNS neurons of their encounter with activated T cells have been investigated in several experimental systems, including ex vivo co-cultures, electrophysiology, and in vivo imaging. Here, we review the modalities of neuron/T cell interactions. We substantiate the contention that T cells are directly responsible for neuronal damage in a large number of neurological diseases and discuss mechanisms of neuronal damage mediated by distinct T cell subsets, the …

Nervous systemMultiple SclerosisT cell[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyAntigen presentationCentral nervous systemInflammationAdaptive ImmunityBiology[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Nervous System03 medical and health sciences0302 clinical medicineT-Lymphocyte Subsets[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]medicineAnimalsHumansEncephalitis Viral030304 developmental biologyNeuronsAntigen PresentationImmunity Cellular0303 health sciencesGeneral NeuroscienceHistocompatibility Antigens Class Iapoptosis[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyT cellNeurodegenerative DiseasesAcquired immune systemcentral nervous systemneuron3. Good healthmedicine.anatomical_structurenervous system[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunologyinflammation[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunologyencephalomyelitisNeuronNervous System Diseasesmedicine.symptomNeuroscience030217 neurology & neurosurgeryEx vivo
researchProduct

MAPK3 deficiency drives autoimmunity via DC arming.

2010

DC are professional APC that instruct T cells during the inflammatory course of EAE. We have previously shown that MAPK3 (Erk1) is important for the induction of T-cell anergy. Our goal was to determine the influence of MAPK3 on the capacity of DC to arm T-cell responses in autoimmunity. We report that DC from Mapk3(-/-) mice have a significantly higher membrane expression of CD86 and MHC-II and--when loaded with the myelin oligodendrocyte glycoprotein--show a superior capacity to prime naive T cells towards an inflammatory phenotype than Mapk3(+/+) DC. Nonetheless and as previously described, Mapk3(-/-) mice were only slightly but not significantly more susceptible to myelin oligodendrocyt…

Encephalomyelitis Autoimmune ExperimentalMAP Kinase Signaling SystemOvalbuminImmunologyMedizinAutoimmunityMice TransgenicT-Cell Antigen Receptor SpecificityBiologymedicine.disease_causeAutoimmunityMyelinMiceImmune systemT-Lymphocyte SubsetsmedicineImmunology and AllergyAnimalsNeuroinflammationGlycoproteinsCD86Mitogen-Activated Protein Kinase 3KinaseHistocompatibility Antigens Class IIDendritic Cellsmedicine.diseaseOligodendrocytePeptide FragmentsSpecific Pathogen-Free OrganismsMice Inbred C57BLmedicine.anatomical_structureRadiation ChimeraImmunologyCytokinesMyelin-Oligodendrocyte GlycoproteinB7-2 AntigenInfiltration (medical)European journal of immunology
researchProduct

The role of NFATc2 in chronic autoimmune neuroinflammation

2014

Dimethyl fumarate (DMF), a fumaric acid ester with potential immunomodulatory and neuroprotective effect, was recently approved as treatment for relapsing–remitting multiple sclerosis (MS). DMF ameliorates the clinical course of experimental autoimmune encephalomyelitis (EAE), the murine model of MS, where it exerts a neuroprotective action, reducing demyelination and axonal loss. We hypothesized that these effects are mediated, at least in part, through its action on microglia. We used a microglial cell line (N9) activated with lipopolysaccharide (LPS) to analyze the effect of monomethyl fumarate (MMF), a bioactive metabolite of DMF, in vitro. We show that MMF reverts the molecular phenoty…

MicrogliaDimethyl fumarateChemistryImmunologyExperimental autoimmune encephalomyelitisInflammationPharmacologymedicine.diseaseNeuroprotectionchemistry.chemical_compoundmedicine.anatomical_structureNeurologyCX3CR1medicineImmunology and AllergyNeurology (clinical)medicine.symptomReceptorNeuroinflammationJournal of Neuroimmunology
researchProduct

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS

2020

ObjectiveTo investigate the association of serum neurofilament light chain (sNfL) levels with CSF parameters in clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS), taking into account radiologic and clinical parameters of disease activity.MethodsSimultaneously collected serum and CSF samples of 112 untreated patients newly diagnosed with CIS or RRMS were included in this cross-sectional study. CSF parameters were obtained as part of routine diagnostic tests. sNfL levels of patients and of 62 healthy donors were measured by highly sensitive single molecule array (SiMoA) immunoassay.ResultsPatients with RRMS (n = 91, median 10.13 pg/mL, interquartile range [IQR] 6.67–1…

AdultMalemedicine.medical_specialty41LeukocytosisNeurofilament lightInflammationIntrathecalGastroenterologyArticleLeukocyte CountMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansPleocytosisInflammationClinically isolated syndromemedicine.diagnostic_testbusiness.industryAxonsHighly sensitiveCross-Sectional StudiesNeurologyImmunoglobulin GImmunoassayFemaleNeurology (clinical)medicine.symptombusinessNeurology - Neuroimmunology Neuroinflammation
researchProduct

BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions

2011

Several lines of evidence indicate that remyelination represents one of the most effective mechanisms to achieve axonal protection. For reasons that are not yet understood, this process is often incomplete or fails in multiple sclerosis (MS). Activated astrocytes appear to be able to boost or inhibit endogenous repair processes. A better understanding of remyelination in MS and possible reasons for its failure is needed. Using the well-established toxic demyelination cuprizone model, we created lesions with either robust or impaired endogenous remyelination capacity. Lesions were analyzed for mRNA expression levels by Affymetrix GeneChip® arrays. One finding was the predominance of immune a…

MalePathologyPlatelet-derived growth factormedicine.medical_treatmentCell CountBehavioral Neurosciencechemistry.chemical_compoundMice0302 clinical medicineFluorescent Antibody Technique IndirectOligonucleotide Array Sequence AnalysisPlatelet-Derived Growth Factor0303 health sciencesGlial fibrillary acidic proteinbiologyExperimental autoimmune encephalomyelitisAstrocytomaMiddle AgedImmunohistochemistrymedicine.anatomical_structureFemaleFibroblast Growth Factor 2Fatty Acid-Binding Protein 7Adultmedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisImmunologyBlotting WesternNerve Tissue ProteinsFatty Acid-Binding ProteinsReal-Time Polymerase Chain ReactionTransfection03 medical and health sciencesCuprizoneCell Line TumorGlial Fibrillary Acidic ProteinmedicineAnimalsHumansRNA MessengerRemyelination030304 developmental biologyAgedEndocrine and Autonomic SystemsMultiple sclerosisGrowth factorTumor Suppressor Proteinsmedicine.diseaseOligodendrocyteMice Inbred C57BLchemistryAstrocytesbiology.proteinOsteopontinCarrier Proteins030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4

2015

A body of experimental evidence suggests that T cells mediate neuroprotection following CNS injury; however, the antigen specificity of these T cells and how they mediate neuroprotection are unknown. Here, we have provided evidence that T cell-mediated neuroprotection after CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell receptors (TCRs). Using two murine models of CNS injury, we determined that damage-associated molecular mediators that originate from injured CNS tissue induce a population of neuroprotective, IL-4-producing T cells in an antigen-independent fashion. Compared with wild-type mice, IL-4-deficient animals had decreased functi…

CD4-Positive T-LymphocytesCancer ResearchMAP Kinase Signaling SystemPopulationReceptors Antigen T-CellInflammationBiologyNeuroprotectionMiceAntigenClinical investigationAnimalsMedicineExtracellular Signal-Regulated MAP KinaseseducationReceptorInterleukin 4Mice Knockouteducation.field_of_studybusiness.industryT-cell receptorHistocompatibility Antigens Class IINeurodegenerative DiseasesGeneral MedicineAxonsCell biologyBrain InjuriesMyeloid Differentiation Factor 88Immunologybiology.proteinInterleukin-4medicine.symptomFunction and Dysfunction of the Nervous SystemCorrigendumbusinessProto-Oncogene Proteins c-aktResearch ArticleNeurotrophinJournal of Clinical Investigation
researchProduct

Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.

2016

Objective: Natalizumab is known to prevent T-helper cells entering the central nervous system (CNS). We hypothesize that more pathogenic T-helper cells are present outside the CNS and a possible relationship to disease severity. Methods: Characterization and enrichment of human CD4+IL-17+ cells were performed ex vivo using peripheral blood mononuclear cells from natalizumab-treated relapsing-remitting multiple sclerosis (RRMS) patients ( n = 33), untreated RRMS patients ( n = 13), and healthy controls ( n = 33). Magnetic resonance imaging (MRI) scans were performed routinely for patients. Results: Lymphocytes were elevated in peripheral blood of natalizumab-treated patients compared to untr…

0301 basic medicineAdultCD4-Positive T-LymphocytesCentral Nervous SystemMaleMultiple SclerosisAdolescentFulminantCellCentral nervous systemPeripheral blood mononuclear cell03 medical and health sciencesYoung Adult0302 clinical medicineNatalizumabmedicineHumansbusiness.industryMultiple sclerosisNatalizumabInterleukin-17Middle Agedmedicine.disease030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyLeukocytes MononuclearFemaleNeurology (clinical)Interleukin 17business030217 neurology & neurosurgeryEx vivomedicine.drugMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study

2020

Pain is frequent in multiple sclerosis (MS) and includes different types, with neuropathic pain (NP) being most closely related to MS pathology. However, prevalence estimates vary largely, and causal relationships between pain and biopsychosocial factors in MS are largely unknown. Longitudinal studies might help to clarify the prevalence and determinants of pain in MS. To this end, we analyzed data from 410 patients with newly diagnosed clinically isolated syndrome or relapsing-remitting MS participating in the prospective multicenter German National MS Cohort Study (NationMS) at baseline and after 4 years. Pain was assessed by self-report using the PainDETECT Questionnaire. Neuropsychiatri…

Biopsychosocial modelmedicine.medical_specialtyMultiple SclerosisCohort Studies03 medical and health sciences0302 clinical medicine030202 anesthesiologyInternal medicineEpidemiologyPrevalenceHumansMedicineProspective StudiesProspective cohort study610 Medicine &amp; healthFatigueDepression (differential diagnoses)Clinically isolated syndromeDepressionbusiness.industryMultiple sclerosismedicine.diseaseAnesthesiology and Pain MedicineNeurologyNeuropathic painNeurology (clinical)business030217 neurology & neurosurgeryCohort study
researchProduct

The neuroinflammation collection: a vision for expanding neuro-immune crosstalk in Brain

2021

AcademicSubjects/SCI01870Neuroimmunomodulationbusiness.industryBrainCrosstalk (biology)Immune systemSpecial CommentaryAnimalsHumansMedicineAcademicSubjects/MED00310Neurology (clinical)businessNeuroscienceNeuroinflammationBrain
researchProduct

Novel therapeutic options and drug targets in MS

2013

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

DrugPhase iii trialsbusiness.industryMultiple sclerosismedia_common.quotation_subjectPharmacologymedicine.diseaseBioinformaticsCellular and Molecular NeurosciencemedicineNeurology (clinical)businessTumor necrosis factor receptormedia_commonNature Reviews Neurology
researchProduct

Assessment of cortical damage in early multiple sclerosis with quantitative T 2 relaxometry

2016

T2 relaxation time is a quantitative MRI in vivo surrogate of cerebral tissue damage in multiple sclerosis (MS) patients. Cortical T2 prolongation is a known feature in later disease stages, but has not been demonstrated in the cortical normal appearing gray matter (NAGM) in early MS. This study centers on the quantitative evaluation of the tissue parameter T2 in cortical NAGM in a collective of early MS and clinically isolated syndrome (CIS) patients, hypothesizing that T2 prolongation is already present at early disease stages and variable over space, in line with global and focal inflammatory processes in MS. Additionally, magnetization transfer ratio (MTR) mapping was performed for furt…

Pathologymedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingmedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureCerebral cortexIn vivoRegion of interestCortex (anatomy)medicineMolecular MedicineRadiology Nuclear Medicine and imagingMagnetization transferbusiness030217 neurology & neurosurgerySpectroscopyNMR in Biomedicine
researchProduct

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

2018

Background: Monitoring neuronal injury remains one key challenge in early relapsing-remitting multiple sclerosis (RRMS) patients. Upon axonal damage, neurofilament – a major component of the neuro-axonal cytoskeleton – is released into the cerebrospinal fluid (CSF) and subsequently peripheral blood. Objective: To investigate the relevance of serum neurofilament light chain (sNfL) for acute and chronic axonal damage in early RRMS. Methods: sNfL levels were determined in 74 patients (63 therapy-naive) with recently diagnosed clinically isolated syndrome (CIS) or RRMS using Single Molecule Array technology. Standardized 3 T magnetic resonance imaging (MRI) was performed at baseline and 1–3 con…

AdultMalePathologymedicine.medical_specialtyNeurofilamentMultiple SclerosisNeurofilament lightIntermediate FilamentsSeverity of Illness IndexDisease activity03 medical and health sciencesYoung Adult0302 clinical medicineNeuronal damageNeurofilament ProteinsMedicineHumans030212 general & internal medicineNeuronsbusiness.industryMultiple sclerosisNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyBiomarker (medicine)FemaleNeurology (clinical)Atrophybusiness030217 neurology & neurosurgeryClinical progressionBiomarkersMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis

2014

Objective White matter atrophy occurs independently of lesions in multiple sclerosis. In contrast to lesion detection, the quantitative assessment of white matter atrophy in individual patients has been regarded as a major challenge. We therefore tested the hypothesis that white matter atrophy (WMA) is present at the very beginning of multiple sclerosis (MS) and in virtually each individual patient. To find a new sensitive and robust marker for WMA we investigated the relationship between cortical surface area, white matter volume (WMV), and whole-brain-surface-averaged rectified cortical extrinsic curvature. Based on geometrical considerations we hypothesized that cortical curvature increa…

MalePathologyROI region of interestFOV field of viewlcsh:RC346-429ImagingGRAPPA generalized autocalibrating partially parallel acquisitionCortex (anatomy)Image Processing Computer-AssistedFA fractional anisotropyWMV white matter volumeTE echo timeCerebral Cortexmedicine.diagnostic_testEVAL Münster Neuroimaging Evaluation SystemMiddle AgedMagnetic Resonance ImagingWhite MatterTR repetition timemedicine.anatomical_structureNeurologyGMV gray matter volumeCerebral cortexCortexlcsh:R858-859.7FemaleAlzheimer's diseasePsychologyCIS clinically isolated syndromeMRITSE turbo spin-echoAdultmedicine.medical_specialtyAdolescentCognitive NeuroscienceCortical curvatureICV intracranial volumelcsh:Computer applications to medicine. Medical informaticsCurvatureArticleEDSS Expanded Disability Status ScaleMultiple sclerosisWhite matterYoung AdultAtrophyAlzheimer DiseasemedicineHumansRadiology Nuclear Medicine and imagingWM white matterlcsh:Neurology. Diseases of the nervous systemAgedMultiple sclerosis3D three-dimensionaleWMV estimated white matter volumeMagnetic resonance imagingmedicine.diseaseΔWMV WMV − eWMVCI confidence intervalCase-Control StudiesGM gray matterAnisotropyDTI diffusion tensor imagingNeurology (clinical)AtrophySD standard deviationDemyelinating DiseasesNeuroImage: Clinical
researchProduct

Expanding Two-Photon Intravital Microscopy to the Infrared by Means of Optical Parametric Oscillator

2010

Chronic inflammation in various organs, such as the brain, implies that different subpopulations of immune cells interact with the cells of the target organ. To monitor this cellular communication both morphologically and functionally, the ability to visualize more than two colors in deep tissue is indispensable. Here, we demonstrate the pronounced power of optical parametric oscillator (OPO)-based two-photon laser scanning microscopy for dynamic intravital imaging in hardly accessible organs of the central nervous and of the immune system, with particular relevance for long-term investigations of pathological mechanisms (e.g., chronic neuroinflammation) necessitating the use of fluorescent…

Materials scienceOptical PhenomenaInfrared RaysInfraredGreen Fluorescent ProteinsSpectroscopy Imaging and Other TechniquesBiophysicsColorCell Linelaw.inventionMiceOpticsTwo-photon excitation microscopylawAluminum OxideAnimalsTitaniumMicroscopyPhotonsPhotobleachingbusiness.industryLasersLaserPhotobleachingFluorescenceMolecular ImagingLuminescent ProteinsBiophysicsOptical parametric oscillatorbusinessExcitationIntravital microscopyBiophysical Journal
researchProduct

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

2021

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particular…

Position statementmedicine.medical_specialtytreatment recommendationMedizin610 Medicine & healthReviewDiseasemultiple sclerosis03 medical and health sciences0302 clinical medicineWhite paperNeuronal damagemedicine030212 general & internal medicineRC346-429610 Medicine &amp; healthIntensive care medicinePharmacologybusiness.industryMultiple sclerosisDisease mechanismsGuidelinemedicine.diseasedisease-modifying therapy3. Good healthGroup treatmentNeurologyNeurology. Diseases of the nervous systemNeurology (clinical)businessguideline030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

Remyelinating strategies in multiple sclerosis.

2014

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disorder of the CNS characterized by infiltration of immune cells and progressive damage to myelin sheaths and neurons. In recent years, the importance of the neuronal compartment in the early pathology of multiple sclerosis has become increasingly clear. Direct axonal damage within the early stages of inflammation as well as neuronal injury as a result of chronic demyelination are essential factors for the development of long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has significant implications for treatment, with remyelination of denuded axons to protect neurons from dam…

Multiple SclerosisInflammationBiologyNeuroprotectionImmune systemmedicineHumansPharmacology (medical)RemyelinationDemyelinating DisorderMyelin SheathNeuronsGeneral NeuroscienceMultiple sclerosisNeurodegenerationmedicine.diseaseAxonsPathology of multiple sclerosisOligodendrogliamedicine.anatomical_structurenervous systemImmunologyNeurology (clinical)medicine.symptomNeuroscienceImmunosuppressive AgentsDemyelinating DiseasesExpert review of neurotherapeutics
researchProduct

Long-term performance of the bovine pericardium patch in conventional carotid endarterectomy.

2014

Objective The aim of the study was to analyze long-term results of carotid endarterectomy (CEA) using bovine pericardium patch. Patients and Methods This study is a retrospective analysis of 274 consecutive cases (173 in CEA group and 101 patients in an internal control group of eversion endarterectomy [EEA]) operated between January 2005 and May 2007. Operations were performed according to standard surgical technique. Primary endpoints of the study were 30-day mortality, ipsilateral neurologic event rate, and high-grade restenosis in the long-term follow-up. Results No statistically significance between both groups was found in terms of gender, age, risk factors, medication (statine, plate…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCarotid endarterectomyKaplan-Meier EstimateRestenosisRecurrenceRisk FactorsInternal medicinemedicinePericardiumAnimalsHumansCarotid StenosisStrokeEndarterectomyAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overEndarterectomy Carotidbusiness.industryProportional hazards modelRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseaseSurgeryStrokemedicine.anatomical_structureTreatment OutcomeIschemic Attack TransientCardiologySurgeryCattleFemaleCardiology and Cardiovascular MedicinebusinessPericardiumThe Thoracic and cardiovascular surgeon
researchProduct

Class II HLA interactions modulate genetic risk for multiple sclerosis

2015

Association studies have greatly refined the understanding of how variation within the human leukocyte antigen (HLA) genes influences risk of multiple sclerosis. However, the extent to which major effects are modulated by interactions is poorly characterized. We analyzed high-density SNP data on 17,465 cases and 30,385 controls from 11 cohorts of European ancestry, in combination with imputation of classical HLA alleles, to build a high-resolution map of HLA genetic risk and assess the evidence for interactions involving classical HLA alleles. Among new and previously identified class II risk alleles (HLA-DRB1*15:01, HLA-DRB1*13:03, HLA-DRB1*03:01, HLA-DRB1*08:01 and HLA-DQB1*03:02) and cla…

Geneticsmusculoskeletal diseasesMultiple SclerosisHistocompatibility Antigens Class IISingle-nucleotide polymorphismGenome-wide association studyEpistasis GeneticHuman leukocyte antigenBiologyPolymorphism Single NucleotideArticleHistocompatibilityGenetic variationGeneticsHumansGenetic Predisposition to DiseaseAllele10. No inequalityHLA-DRB1AllelesGenetic association
researchProduct

Functional connectivity analysis using whole brain and regional network metrics in MS patients

2016

In the present study we investigated brain network connectivity differences between patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls (HC) as derived from functional resonance magnetic imaging (fMRI) using graph theory. Resting state fMRI data of 18 RRMS patients (12 female, mean age ± SD: 42 ± 12.06 years) and 25 HC (8 female, 29.2 ± 5.38 years) were analyzed. In order to obtain information of differences in entire brain network, we focused on both, local and global network connectivity parameters. And the regional connectivity differences were assessed using regional network parameters. RRMS patients presented a significant increase of modularity in comparis…

AdultMaleModularity (networks)Resting state fMRIInformation processingBrainCognitionSuperior parietal lobuleMiddle AgedMagnetic Resonance Imaging030218 nuclear medicine & medical imagingCorrelation03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineImage Processing Computer-AssistedHumansFemaleNerve NetPsychologyInsulaNeuroscience030217 neurology & neurosurgeryClustering coefficient2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
researchProduct

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

2021

AbstractBackgroundMultiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants.MethodsTwo multi-center cohort studies (nNationMS=946, nBIONAT=991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients.ResultsHigh serum vitD was associated with reduced MSSS (PNationMS=0.021; PBIONAT=0.007) and reduced ris…

medicine.medical_specialty610 Medicine & healthDiseaseGastroenterologyLesionImmune systemInterferonInternal medicineVitamin D and neurologyMedicineddc:610610 Medicine &amp; healthBeneficial effectsSunlightSystemic lupus erythematosusMultidisciplinaryLow latitudebusiness.industryMultiple sclerosismedicine.diseaseddc:Cardiovascular and Metabolic DiseasesDisease riskmedicine.symptombusinessmedicine.drugCohort study
researchProduct

Is APOE ε4 associated with cognitive performance in early MS?

2020

ObjectiveTo assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).MethodsThis multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memo…

OncologyApolipoprotein Emedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testPaced Auditory Serial Addition Testbusiness.industryMultiple sclerosisCognitionMcDonald criteria610 Medicine & healthmedicine.diseaseNeurologyInternal medicinemedicineddc:610Neurology (clinical)Effects of sleep deprivation on cognitive performance610 Medicine &amp; healthFunction and Dysfunction of the Nervous SystembusinessCohort study
researchProduct

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

2019

ObjectiveWe explored the incremental value of adding multiple disease activity biomarkers in CSF and serum for distinguishing MRI-based benign from aggressive MS in early disease course.MethodsNinety-three patients diagnosed with clinically isolated syndrome (CIS) or early MS were divided into 3 nonoverlapping severity groups defined by objective MRI criteria. Ninety-seven patients with noninflammatory neurologic disorders and 48 patients with other inflammatory neurologic diseases served as controls. Leukocyte subsets in the CSF were analyzed by flow cytometry. CSF neurofilament light chain (NfL) and chitinase-3-like protein 1 (CHI3L1) levels were measured by ELISA. Serum NfL levels were e…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyAdolescent41medicine.medical_treatmentCHI3L1ArticleFlow cytometryCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineText miningMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsMedicineHumansB cellAgedCD20Aged 80 and overB-LymphocytesClinically isolated syndromebiologymedicine.diagnostic_testbusiness.industryMultiple sclerosisImmunotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAxons030104 developmental biologymedicine.anatomical_structureCross-Sectional StudiesNeurologybiology.proteinDisease ProgressionFemaleNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating DiseasesNeurology(R) neuroimmunologyneuroinflammation
researchProduct

No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis

2011

AdultMalePrionsChromosomes Human Pair 20Primary Progressive Multiple SclerosisPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)HumansMedicineGenetic Predisposition to DiseasePrion proteinCodonGene030304 developmental biologyGenetics0303 health sciencesbusiness.industryMiddle AgedMultiple Sclerosis Chronic ProgressivePrnp geneFemaleNeurology (clinical)business030217 neurology & neurosurgeryArchives of Neurology
researchProduct

A lymphocyte-glia connection sets the pace for smoldering inflammation

2021

Successful therapeutic options directly targeting disability progression in patients with multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system, are lacking. Now, a study published in Nature by Absinta and colleagues profiles a lymphocyte-glia connection at the edge of chronic active lesions that continuously drives neurodegenerative pathways.

Chronic ActiveLymphocyteMultiple sclerosisCentral nervous systemInflammationBiologymedicine.diseaseChronic inflammatory disorderGeneral Biochemistry Genetics and Molecular Biologymedicine.anatomical_structuremedicineIn patientDisability progressionmedicine.symptomNeuroscienceCell
researchProduct

Characterization of Th17 cells in multiple sclerosis patients and healthy controls

2014

Pathologymedicine.medical_specialtyNeurologybusiness.industryMultiple sclerosisImmunologymedicineImmunology and AllergyNeurology (clinical)businessmedicine.diseaseJournal of Neuroimmunology
researchProduct

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients

2020

Background: Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration. Objective: Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk. Methods: Cerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiol…

CellCell Countprogressive multifocal leukoencephalopathycerebrospinal fluidMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineNatalizumabCerebrospinal fluidmedicineHumansJCV index030304 developmental biology0303 health sciencesbiologybusiness.industryNatalizumabMultiple sclerosisProgressive multifocal leukoencephalopathyLeukoencephalopathy Progressive MultifocalJCPyVmedicine.diseaseJC VirusCSF cell countstissue-resident memory cellsBlockadeclinical activityTitermedicine.anatomical_structureNeurologyImmunologybiology.proteinNeurology (clinical)AntibodybusinessOriginal Research Papers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Ablagerung von gadoliniumhaltigen Kontrastmitteln im Gehirn nach mehrfacher Anwendung: Konsequenzen für den Einsatz der MRT bei Diagnosestellung und …

2016

Neue Studienergebnisse weisen auf einen Zusammenhang zwischen wiederholten kontrastmittel-unterstutzen MRT-Untersuchungen und Ablagerung gadoliniumhaltiger Kontrastmittel im zentralen Nervensystem hin. Ein wesentlicher Faktor hierbei stellt moglicherweise die zum Einsatz kommende Kontrastmittelsubstanzklasse (linear bzw. makrozyklisch) dar. Uber die letzten Jahrzehnte hat sich die MRT als ein unverzichtbarer Bestandteil in der Diagnostik, aber auch in der Verlaufsbeurteilung unterschiedlicher Erkrankungen etabliert. Dies gilt im besonderen Mase fur chronische Erkrankungen, wie die Multiple Sklerose. Wiederholte MRT-Untersuchungen spielen hier insbesondere durch die zunehmenden Therapieoptio…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industrymedicineNeurology (clinical)business030217 neurology & neurosurgeryMultiple skleroseAktuelle Neurologie
researchProduct

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy

2020

OBJECTIVE: Adult drug-resistant epilepsy (DRE) is associated with significant morbidity. Infiltration of immune cells is observed in DRE epileptic foci; however, the relation between DRE and the peripheral immune cell compartment remains only partially understood. We aimed to investigate differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well-controlled epilepsy (WCE). METHODS: Peripheral blood mononuclear cells and serum from >120 age- and sex-matched adults suffering from focal onset epilepsy and controls were analyzed by multipanel flow cytometry, multiplex i…

AdultCD4-Positive T-LymphocytesMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_treatmenturologic and male genital diseasesPeripheral blood mononuclear cellProinflammatory cytokineInterferon-gammaYoung Adult03 medical and health sciencesEpilepsyTh2 Cells0302 clinical medicineImmune systemNeurofilament ProteinsmedicineHumansImmunoassayInflammationEpilepsyTumor Necrosis Factor-alphabusiness.industryInterleukinsInterleukin-17NeurotoxicityGranulocyte-Macrophage Colony-Stimulating FactorInterleukinMiddle AgedFlow Cytometrymedicine.diseaseSingle Molecule ImagingCD4 Lymphocyte CountInterleukin-10030104 developmental biologyCytokineNeurologyCase-Control StudiesImmunologyCytokinesTh17 CellsFemaleTumor necrosis factor alphaInterleukin-4Neurology (clinical)business030217 neurology & neurosurgery
researchProduct

Two-photon microscopy and neuroinflammation: Crosstalk between T cells and neurons

2014

PhysicsCrosstalk (biology)NeurologyTwo-photon excitation microscopyImmunologyBiophysicsImmunology and AllergyNeurology (clinical)NeuroinflammationJournal of Neuroimmunology
researchProduct

Multiple sclerosis – candidate mechanisms underlying CNS atrophy

2009

Recently it has become clear that the neuronal compartment plays a more important role than previously thought in the pathology of multiple sclerosis. Apart from demyelination, neuronal pathology is apparently largely responsible for the brain atrophy that can be observed early on and throughout the course of the disease. The loss of axons and their neurons in the course of chronic neuroinflammation is a major factor determining long-term disability in patients. The actual steps leading from immune attack against the myelin sheath to neuronal damage are not yet fully clear. Here we review key findings about direct axonal damage processes, demyelination-related neuronal pathology and cell-bo…

NeuronsPathologymedicine.medical_specialtyMultiple SclerosisGeneral NeuroscienceMultiple sclerosisCompartment (ship)DiseaseBiologymedicine.diseaseAxonsPathology of multiple sclerosisAtrophyImmune systemnervous systemMyelin sheathDisease ProgressionmedicineHumansAtrophyNeuroscienceMyelin SheathNeuroinflammationTrends in Neurosciences
researchProduct

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

2013

Importance Although multiple sclerosis (MS) has long been considered the prototype for an inflammatory, demyelinating disease of the central nervous system, modern histopathology and imaging techniques show that significant damage to neuronal structures already start occurring in the earliest stages of the disease. As the disease progresses, the extent of neuronal pathology accumulates. Therapeutic progress in terms of the prevention of increased disability has only just begun. Objective To review possible diagnostic improvements of neuronal compartment pathology as well as direct therapeutic interventions based on reports from the last decade and outline clinical results from studies and p…

NeuronsMultiple Sclerosisbusiness.industryMultiple sclerosisCentral nervous systemAnti-Inflammatory AgentsDiseasemedicine.diseaseNeuroprotectionClinical trialmedicine.anatomical_structureNeuronal damageNerve DegenerationDemyelinating diseasemedicineDisease ProgressionHumansIdentification (biology)Neurology (clinical)businessNeuroscienceJAMA neurology
researchProduct

FRET based ratiometric Ca(2+) imaging to investigate immune-mediated neuronal and axonal damage processes in experimental autoimmune encephalomyeliti…

2015

Abstract Background Irreversible axonal and neuronal damage are the correlate of disability in patients suffering from multiple sclerosis (MS). A sustained increase of cytoplasmic free [Ca2+] is a common upstream event of many neuronal and axonal damage processes and could represent an early and potentially reversible step. New method We propose a method to specifically analyze the neurodegenerative aspects of experimental autoimmune encephalomyelitis by Forster Resonance Energy Transfer (FRET) imaging of neuronal and axonal Ca2+ dynamics by two-photon laser scanning microscopy (TPLSM). Results Using the genetically encoded Ca2+ sensor TN-XXL expressed in neurons and their corresponding axo…

NeuronsEncephalomyelitis Autoimmune ExperimentalMicroscopy ConfocalChemistryGeneral NeuroscienceMultiple sclerosisNeurodegenerationCellExperimental autoimmune encephalomyelitismedicine.diseaseAxonsMicemedicine.anatomical_structureFörster resonance energy transfernervous systemIn vivoCytoplasmmedicineFluorescence Resonance Energy TransferAnimalsCalciumAxonNeuroscienceBrain StemJournal of neuroscience methods
researchProduct

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria

2018

MRI has been formally included in the diagnostic work-up of patients with a suspicion of multiple sclerosis (MS) in 2001, to demonstrate disease dissemination in space (DIS) and time (DIT) and to exclude alternative diagnoses.1 Over time, these criteria have been modified to simplify their use and to clarify specific aspects (eg, spinal cord findings).2 One aspect marginally analysed in the diagnostic work-up of patients with clinically isolated syndrome (CIS) is the role of intracortical lesions (ICLs), which are a prominent feature of MS and contribute to disability and cognitive impairment.2 A single-centre study3 showed that inclusion of ICL for the evaluation of DIS in CIS increased th…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime Factorsmultiple sclerosis030218 nuclear medicine & medical imagingCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineMedicineHumansMRI; multiple sclerosisProspective StudiesMedical diagnosisProspective cohort studymriCerebral CortexClinically isolated syndromemedicine.diagnostic_testbusiness.industryMultiple sclerosisBrainMagnetic resonance imagingMiddle Agedmedicine.diseaseInstitutional review boardMagnetic Resonance ImagingSurgeryPsychiatry and Mental healthSpinal CordCohortSurgeryFemaleNeurology (clinical)Radiologybusiness030217 neurology & neurosurgeryMRICohort studyDemyelinating Diseases
researchProduct

Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis

2018

Abstract Background The number of white matter lesions (WML) in brain MRI is the most established paraclinical tool to support the diagnosis of multiple sclerosis (MS) and to monitor its course. Diagnostic criteria have stipulated a minimum detectable diameter of 3 mm per WML, although this threshold is not evidence-based. We aimed to provide a rationale for a WML size threshold for three-dimensional MRI sequences at 3 T by comparing patients with relapsing-remitting MS (RRMS) to control subjects (CS). Methods We analyzed MR images from two cohorts, obtained at scanners from two different vendors, each comprising patients with RRMS and CS. Both cohorts were examined with FLAIR and T1w seque…

AdultMaleWhite matter lesionNeuroimagingFluid-attenuated inversion recoveryYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineHumansMedicine030212 general & internal medicineRetrospective StudiesExpanded Disability Status ScaleReceiver operating characteristicbusiness.industryMultiple sclerosisGeneral MedicineOdds ratioReference Standardsmedicine.diseaseMagnetic Resonance ImagingWhite MatterHyperintensityNeurologyRelapsing remittingFemaleNeurology (clinical)businessNuclear medicine030217 neurology & neurosurgeryMultiple Sclerosis and Related Disorders
researchProduct

Parallelized TCSPC for dynamic intravital fluorescence lifetime imaging : quantifying neuronal dysfunction in neuroinflammation

2013

Two-photon laser-scanning microscopy has revolutionized our view on vital processes by revealing motility and interaction patterns of various cell subsets in hardly accessible organs (e.g. brain) in living animals. However, current technology is still insufficient to elucidate the mechanisms of organ dysfunction as a prerequisite for developing new therapeutic strategies, since it renders only sparse information about the molecular basis of cellular response within tissues in health and disease. In the context of imaging, Forster resonant energy transfer (FRET) is one of the most adequate tools to probe molecular mechanisms of cell function. As a calibration-free technique, fluorescence lif…

Central Nervous SystemDiagnostic ImagingFluorescence-lifetime imaging microscopyPathologymedicine.medical_specialtyMouseScienceBiophysicsMedizinNeurophysiologyContext (language use)NeuroimagingBiosensing TechniquesBiologyIn Vitro TechniquesMiceCalcium imagingModel OrganismsMicroscopyMolecular Cell BiologyNeurobiology of Disease and RegenerationMedical imagingmedicineFluorescence Resonance Energy TransferAnimalsBiologyNeuroinflammationMultidisciplinaryPhysicsQRBrainAnimal ModelsIntravital ImagingCalcium ImagingFörster resonance energy transferMedicineCalciumFunction and Dysfunction of the Nervous SystemNeuroscienceResearch ArticleNeuroscience
researchProduct

Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System

2015

SummaryDuring early embryogenesis, microglia arise from yolk sac progenitors that populate the developing central nervous system (CNS), but how the tissue-resident macrophages are maintained throughout the organism’s lifespan still remains unclear. Here, we describe a system that allows specific, conditional ablation of microglia in adult mice. We found that the microglial compartment was reconstituted within 1 week of depletion. Microglia repopulation relied on CNS-resident cells, independent from bone-marrow-derived precursors. During repopulation, microglia formed clusters of highly proliferative cells that migrated apart once steady state was achieved. Proliferating microglia expressed …

Central Nervous SystemCellular differentiationCentral nervous systemInterleukin-1betaImmunologyCX3C Chemokine Receptor 1Bone Marrow CellsBiologyMiceCell MovementCX3CR1medicineAnimalsImmunology and AllergyProgenitor cellNeuroinflammationCell ProliferationReceptors Interleukin-1 Type IMicrogliaBase SequenceTumor Necrosis Factor-alphaMacrophagesCell DifferentiationSequence Analysis DNAHematopoietic Stem CellsCell biologyMice Inbred C57BLmedicine.anatomical_structureInfectious DiseasesImmunologyTumor necrosis factor alphaReceptors ChemokineMicrogliaSignal transductionSignal TransductionImmunity
researchProduct

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

2013

International audience; Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10(-4)). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10(-8)), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variant…

Multiple SclerosisGenotype[SDV]Life Sciences [q-bio]European Continental Ancestry GroupGenome-wide association studyCLEC16ABiologymultiple sclerosisMajor histocompatibility complexPolymorphism Single NucleotideArticleWhite People03 medical and health sciences0302 clinical medicineResearch Support N.I.H. ExtramuralGene FrequencyPolymorphism (computer science)Journal ArticleGeneticsmedicineHumansGenetic Predisposition to DiseaseAlleleGenotypingAllele frequency030304 developmental biologyGenetics0303 health sciencesResearch Support Non-U.S. Gov'tMultiple sclerosisChromosome MappingGenetic Variationmedicine.disease3. Good healthGenetic Locibiology.protein030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyGenome-Wide Association Study
researchProduct

Casein kinase 2 governs the molecular decision between Th17 cell and Treg cell development and controls encephalitogenicity of Th17 cells in experime…

2014

medicine.anatomical_structureNeurologyImmunologyExperimental autoimmune encephalomyelitisCellmedicineImmunology and AllergyNeurology (clinical)BiologyCasein kinase 2medicine.diseaseTreg cellCell biologyJournal of Neuroimmunology
researchProduct

Dendritic cells tip the balance towards induction of regulatory T cells upon priming in experimental autoimmune encephalomyelitis

2016

Counter-balancing regulatory mechanisms, such as the induction of regulatory T cells (Treg), limit the effects of autoimmune attack in neuroinflammation. However, the role of dendritic cells (DCs) as the most powerful antigen-presenting cells, which are intriguing therapeutic targets in this context, is not fully understood. Here, we demonstrate that conditional ablation of DCs during the priming phase of myelin-specific T cells in experimental autoimmune encephalomyelitis (EAE) selectively aborts inducible Treg (iTreg) induction, whereas generation of T helper (Th)1/17 cells is unaltered. DCs facilitate iTreg induction by creating a milieu with high levels of interleukin (IL)-2 due to a st…

0301 basic medicineEncephalomyelitis Autoimmune ExperimentalImmunologyMedizinPriming (immunology)chemical and pharmacologic phenomenaAutoimmunitymedicine.disease_causeLymphocyte ActivationT-Lymphocytes RegulatoryAutoimmunityImmunomodulation03 medical and health sciencesMice0302 clinical medicineT-Lymphocyte SubsetsTransforming Growth Factor betamedicineImmunology and AllergyAnimalsNeuroinflammationCD40biologyMultiple sclerosisExperimental autoimmune encephalomyelitisInterleukinhemic and immune systemsDendritic Cellsmedicine.disease030104 developmental biologyImmunologybiology.proteinInterleukin 12CytokinesTh17 Cells030217 neurology & neurosurgery
researchProduct

In Vivo Imaging of Partially Reversible Th17 Cell-Induced Neuronal Dysfunction in the Course of Encephalomyelitis

2010

SummaryNeuronal damage in autoimmune neuroinflammation is the correlate for long-term disability in multiple sclerosis (MS) patients. Here, we investigated the role of immune cells in neuronal damage processes in animal models of MS by monitoring experimental autoimmune encephalomyelitis (EAE) by using two-photon microscopy of living anaesthetized mice. In the brainstem, we detected sustained interaction between immune and neuronal cells, particularly during disease peak. Direct interaction of myelin oligodendrocyte glycoprotein (MOG)-specific Th17 and neuronal cells in demyelinating lesions was associated with extensive axonal damage. By combining confocal, electron, and intravital microsc…

Cell signalingPathologymedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalEncephalomyelitisImmunologyApoptosisCell CommunicationBiologyReceptors N-Methyl-D-AspartateMyelin oligodendrocyte glycoproteinMiceImmune systemCell MovementmedicineAnimalsImmunology and AllergyNeuroinflammationCells CulturedNeuronsMultiple sclerosisExperimental autoimmune encephalomyelitisInterleukin-17T-Lymphocytes Helper-Inducermedicine.diseaseAxonsCell biologyMice Inbred C57BLInfectious Diseasesnervous systemSynapsesbiology.proteinCalciumIntravital microscopyImmunity
researchProduct

The potential of serum neurofilament as biomarker for multiple sclerosis

2021

Abstract Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerativ…

Oncologymedicine.medical_specialtyTreatment responseMultiple SclerosisNeurofilamentFilaments citoplasmàticsDiseaseneurofilamentUpdatesNeurofilament ProteinsInternal medicinemedicineHumans:aminoácidos péptidos y proteínas::proteínas::aminoácidos péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS]Longitudinal StudiesSubclinical disease:Diagnosis::Prognosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Esclerosi múltiple - Imatgeria per ressonància magnètica:diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings]AcademicSubjects/SCI01870business.industrytherapy responseMultiple sclerosis:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]biomarkers:Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores]:Amino Acids Peptides and Proteins::Proteins::Amino Acids Peptides and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS]Prognosismedicine.diseaseEsclerosi múltiple - PrognosiMagnetic Resonance ImagingClinical trialEarly results:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Biomarker (medicine)AcademicSubjects/MED00310Neurology (clinical)businessBrain
researchProduct

Correspondence to Sand et al. “Critical Reappraisal of a Catechol-O-Methyltransferase Transversion Variant in Schizophrenia”

2010

GeneticsCatechol-O-methyl transferaseSchizophrenia (object-oriented programming)GenotypeBiologyTransversionBiological PsychiatryBiological Psychiatry
researchProduct

The problems and promises of research into human immunology and autoimmune disease

2012

Translational research in autoimmunity is hampered by a number of hurdles, including a lack of knowledge regarding initiating and pathologically relevant autoantigens, the low frequency of autoreactive pathogenic B and T cells, difficulty in accessing the affected tissue, differences between self-reactive and pathogen-specific lymphocytes, a lack of etiologically relevant preclinical animal models and the heterogeneity of disease presentation. Given the need for biomarkers and new therapeutics, it is imperative that these hurdles be surmounted.

T-LymphocytesTranslational researchmedicine.disease_causeAutoantigensGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityAutoimmune DiseasesTranslational Research BiomedicalMiceRisk FactorsmedicineAnimalsHumansLack of knowledgeGenetic Predisposition to DiseaseAutoimmune diseaseB-Lymphocytesbusiness.industryGeneral Medicinemedicine.diseaseDisease Models AnimalDisease PresentationImmunologybusinessBiomarkersGenome-Wide Association Study
researchProduct

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

2018

Background and purpose: Multiple sclerosis (MS) is a complex disease of the central nervous system. As new drugs are becoming available, knowledge on diagnosis and treatment must continuously evolve. There is therefore a need for a reference tool compiling current data on benefit and safety, to aid professionals in treatment decisions and use of resources across Europe. The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined forces to meet this need. The objective was to develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS to guide healthcare professionals in…

medicine.medical_specialtyConsensusMultiple SclerosisdemyelinatingComplex diseasedisease-modifying therapies GRADE methodology guideline Multiple sclerosis Neurology Neurology (clinical)Outcome (game theory)Pharmacological treatmentImmunomodulation03 medical and health sciences0302 clinical medicineIntervention (counseling)GRADE methodologyAgency (sociology)Nominal group techniquemedicineImmunologic FactorsRelevance (law)Humans030212 general & internal medicineneurological disorderdisease-modifying therapiesIntensive care medicineSocieties MedicaldiseaseEvidence-Based Medicinebusiness.industryMultiple sclerosisdisease-modifying treatmentGuidelinemedicine.diseaseresearch methodEuropeNeurologymultiple sclerosiFamily medicinePractice Guidelines as TopicNeurology (clinical)businessguideline030217 neurology & neurosurgeryEuropean journal of neurology
researchProduct

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

2016

Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, lin…

0301 basic medicineProbandMaleGene ExpressionQH426-470multiple sclerosis0302 clinical medicineRisk FactorsGenotypeMissense mutationExomegeneticsguidelinesGenetics (clinical)degradationriskGeneticsLinkagedeficiencyMiddle AgedPenetrance3. Good healthPedigreeplasminogenChromosomes Human Pair 6FemalelinkageAdultGenotype610 Medicine & healthInvestigationsBiologysystemPolymorphism Single Nucleotideblood-brain-barrieractivatorMultiple sclerosisAssociation03 medical and health scienceslamininGenetic linkagemedicineGeneticsHumansAmino Acid Sequenceddc:610Molecular BiologyGenotypingAgeddiseaseSequence Homology Amino AcidMultiple sclerosisCase-control studyassociationPlasminogenmedicine.diseasediagnostic-criteria030104 developmental biologyCase-Control StudiesImmunologySequence Alignment030217 neurology & neurosurgery
researchProduct

Past, present and future of immunology in Mainz.

2016

0301 basic medicine03 medical and health sciences030104 developmental biologyAllergy and ImmunologyGermanyImmunologyMEDLINELibrary scienceHumansBiologyCellular immunology
researchProduct

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current trea…

2018

Approved medications for relapsing-remitting multiple sclerosis have shown to be effective in terms of their anti-inflammatory potential. However, it is also crucial to evaluate what long-term effects a patient can expect from current MS drugs in terms of preventing neurodegeneration. Here we aim to provide an overview of the current treatment strategies in MS with a specific focus on potential neuroprotective effects. Areas covered: Randomized, double-blind and placebo or referral-drug controlled phase 2a/b and phase 3 trials were examined; non-blinded phase 4 studies (extension studies) were included to provide long-term data, if not otherwise available. Endpoints considered were expanded…

Oncologymedicine.medical_specialtyAnti-Inflammatory AgentsNeuroimagingDiseaseNeuropsychological TestsPlaceboNeuroprotectionDisability Evaluation03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineInternal medicineTeriflunomidemedicineHumansPharmacology (medical)030212 general & internal medicineNeuronsExpanded Disability Status Scalebusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseaseMagnetic Resonance ImagingFingolimodNeuroprotective AgentsTreatment OutcomeMultiple sclerosis functional compositechemistryDisease ProgressionNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct

Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells

2011

Summary We previously demonstrated a correlation between the frequency of CX3CR1-expressing human natural killer (NK) cells and disease activity in multiple sclerosis and showed that CX3CR1high NK cells were more cytotoxic than their CX3CR1neg/low counterparts. Here we aimed to determine whether human NK cell fractions defined by CX3CR1 represent distinct subtypes. Phenotypic and functional NK cell analyses revealed that, distinct from CX3CR1high, CX3CR1neg/low NK cells expressed high amounts of type 2 cytokines, proliferated robustly in response to interleukin-2 and promoted a strong up-regulation of the key co-stimulatory molecule CD40 on monocytes. Co-expression analyses of CX3CR1 and CD…

ChemokineInterleukin 21CD40Lymphokine-activated killer cellbiologyImmunologybiology.proteinInterleukin 12Immunology and AllergyCytotoxic T cellNatural killer T cellCell MaturationCell biologyImmunology
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

sj-pdf-4-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-4-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-2-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-2-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

MSJ765666_supplementary_figure_1 – Supplemental material for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in e…

2018

Supplemental material, MSJ765666_supplementary_figure_1 for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis by Nelly Siller, Jens Kuhle, Muthuraman Muthuraman, Christian Barro, Timo Uphaus, Sergiu Groppa, Ludwig Kappos, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal

FOS: Clinical medicine111702 Aged Health CareFOS: Health scienceshumanities110904 Neurology and Neuromuscular Diseases
researchProduct

sj-pdf-1-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-1-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-3-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-3-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

Supplement_TAND_050219 – Supplemental material for Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis

2019

Supplemental material, Supplement_TAND_050219 for Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis by Vinzenz Fleischer, Nabin Koirala, Amgad Droby, René-Maxime Gracien, Ralf Deichmann, Ulf Ziemann, Sven G. Meuth, Muthuraman Muthuraman, Frauke Zipp and Sergiu Groppa in Therapeutic Advances in Neurological Disorders

FOS: Clinical medicine111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct

sj-docx-1-tan-10.1177_17562864211051497 – Supplemental material for Association of serum neurofilament light chain levels and neuropsychiatric manife…

2021

Supplemental material, sj-docx-1-tan-10.1177_17562864211051497 for Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus by Sinah Engel, Simone Boedecker, Paul Marczynski, Stefan Bittner, Falk Steffen, Arndt Weinmann, Andreas Schwarting, Frauke Zipp, Julia Weinmann-Menke and Felix Luessi in Therapeutic Advances in Neurological Disorders

FOS: Clinical medicineskin and connective tissue diseases111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct

sj-pdf-8-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-8-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-3-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-3-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-7-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-7-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-4-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-4-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-5-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-5-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

MSJ763541_supplementary_material – Supplemental material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atroph…

2018

Supplemental material, MSJ763541_supplementary_material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis by Christiane Graetz, Adriane Gröge, Felix Luessi, Anke Salmen, Daniela Zöller, Janine Schultz, Nelly Siller, Vinzenz Fleischer, Barbara Bellenberg, Achim Berthele, Viola Biberacher, Joachim Havla, Michael Hecker, Reinhard Hohlfeld, Carmen Infante-Duarte, Jan S Kirschke, Tania Kümpfel, Ralf Linker, Friedemann Paul, Steffen Pfeuffer, Philipp Sämann, Gerrit Toenges, Frank Weber, Uwe K Zettl, Antje Jahn-Eimermacher, Gisela Antony, Sergiu Groppa, Heinz Wiendl, Bernhard Hemmer, Mark Mühlau, Carsten Lukas, Ralf Gold, Chri…

FOS: Clinical medicine111702 Aged Health CareFOS: Health sciences110904 Neurology and Neuromuscular Diseases
researchProduct

sj-pdf-1-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-1-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-8-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-8-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-docx-1-tan-10.1177_17562864211051497 – Supplemental material for Association of serum neurofilament light chain levels and neuropsychiatric manife…

2021

Supplemental material, sj-docx-1-tan-10.1177_17562864211051497 for Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus by Sinah Engel, Simone Boedecker, Paul Marczynski, Stefan Bittner, Falk Steffen, Arndt Weinmann, Andreas Schwarting, Frauke Zipp, Julia Weinmann-Menke and Felix Luessi in Therapeutic Advances in Neurological Disorders

FOS: Clinical medicineskin and connective tissue diseases111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified110904 Neurology and Neuromuscular Diseases
researchProduct

sj-pdf-2-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-2-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-6-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-6-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-7-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-7-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-5-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-5-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

sj-pdf-6-mso-10.1177_2055217320936318 - Supplemental material for Supplementary medication in multiple sclerosis: Real-world experience and potential…

2020

Supplemental material, sj-pdf-6-mso-10.1177_2055217320936318 for Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement by Katrin Pape, Falk Steffen, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal – Experimental, Translational and Clinical

FOS: Clinical medicine110904 Neurology and Neuromuscular DiseasesNeuroscience
researchProduct

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current trea…

2018

Introduction: Approved medications for relapsing-remitting multiple sclerosis have shown to be effective in terms of their anti-inflammatory potential. However, it is also crucial to evaluate what long-term effects a patient can expect from current MS drugs in terms of preventing neurodegeneration. Here we aim to provide an overview of the current treatment strategies in MS with a specific focus on potential neuroprotective effects. Areas covered: Randomized, double-blind and placebo or referral-drug controlled phase 2a/b and phase 3 trials were examined; non-blinded phase 4 studies (extension studies) were included to provide long-term data, if not otherwise available. Endpoints considered…

researchProduct